<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>A NOVEL HUMAN VIRUS CAUSING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) AND USES THEREOF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inventor(s)</strong></td>
<td>Chan, Kwokhung; Guan, Y; Nicholls, JM; Poon, LLM; Yuen, KY; Leung, FCC</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>WO Published patent application WO 2004085633. World Intellectual Property Organization (WIPO), PatentScope, 2004</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2004</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/177081">http://hdl.handle.net/10722/177081</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
(51) International Patent Classification: C12N 7/00, 7/04, C07H 21/00, C07K 14/165, G01N 33/569, 33/68, C12Q 1/04, A61K 39/215, A61P 31/14, 11/00

(21) International Application Number: PCT/CN2004/000248

(22) International Filing Date: 24 March 2004 (24.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
- 60/457,031 24 March 2003 (24.03.2003) US
- 60/457,730 26 March 2003 (26.03.2003) US
- 60/459,931 2 April 2003 (02.04.2003) US
- 60/460,357 3 April 2003 (03.04.2003) US
- 60/461,265 8 April 2003 (08.04.2003) US
- 60/462,805 14 April 2003 (14.04.2003) US
- 60/464,886 23 April 2003 (23.04.2003) US

(71) Applicant (for all designated States except US): THE UNIVERSITY OF HONG KONG [CN/CN]; G18, Eliot Hall, Pokfulam Road, Hong Kong (CN).

(72) Inventors: CHAN, Kwokhung; 3A, Wisteria Mansion, Tai Kok Shing, Quarry Bay, Hong Kong (CN). GUAN, Yi; 11A, Block 4, Pokfulam Garden, 180 Pokfulam Road, Hong Kong (CN). NICHOLLS, John, Malcolm; 5B Royalton, 118 Pokfulam Road, Pokfulam, Hong Kong (CN). PEIRIS, Joseph, Sryyal, Malik; 19/F, Block 29, Baguio Villa, 550 Victoria Road, Hong Kong (CN). POON, Litman; Flat 21H, Block 2, PHase 3, Belvedere Garden, Tsuen Wan, Hong Kong (CN). YUEN, Kwokying; Flat C, 19/F, Block 20, Baguio Villa, 555 Victoria Road, Pokfulam Road, Hong Kong (CN). LEUNG, Frederick, C.; 24th Floor, Starr Hall, 91B Pokfulam Road, Hong Kong (CN).


(81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published: with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A NOVEL HUMAN VIRUS CAUSING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) AND USES THEREOF

(57) Abstract: The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans ("hSARS virus"). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences.
A NOVEL HUMAN VIRUS CAUSING
SEVERE ACUTE RESPIRATORY SYNDROME (SARS) AND USES THEREOF

This application claims priority benefit to U.S. provisional application no. 60/457,031, filed March 24, 2003; U.S. provisional application no. 60/457,730, filed March 26, 2003; U.S. provisional application no. 60/459,931, filed April 2, 2003; U.S. provisional application no. 60/460,357, filed April 3, 2003; U.S. provisional application no. 60/461,265, filed April 8, 2003; U.S. provisional application no. 60/462,805, filed April 14, 2003; and U.S. provisional application no. 60/464,886 filed April 23, 2003, each of which is incorporated herein by reference in its entirety.

The instant application contains a lengthy Sequence Listing which is being concurrently submitted via triplicate CD-R in lieu of a printed paper copy, and is hereby incorporated by reference in its entirety. Said CD-R, recorded on March 16, 2004, are labeled “CRF”, “Copy 1” and “Copy 2”, respectively, and each contains only one identical 1.58 MB file (V9661069.APP).

1. INTRODUCTION

The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known members of Coronaviridae. The present invention relates to a nucleotide sequence comprising the complete genomic sequence of the hSARS virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the hSARS virus. The invention also relates to the deduced amino acid sequences of the complete genome of the hSARS virus. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods, such as for immunogens. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies directed against polypeptides encoded by the nucleotide sequence. Furthermore, the invention relates to vaccine preparations
comprising the hSARS virus, including recombinant and chimeric forms of said virus as well as protein extracts and subunits of said virus.

2. BACKGROUND OF THE INVENTION.

Recently, there has been an outbreak of atypical pneumonia in Guangdong province in mainland China. Between November 2002 and March 2003, there were 792 reported cases with 31 fatalities (WHO. Severe Acute Respiratory Syndrome (SARS) Weekly Epidemiol Rec. 2003; 78: 86). In response to this crisis, the Hospital Authority in Hong Kong has increased the surveillance on patients with severe atypical pneumonia. In the course of this investigation, a number of clusters of health care workers with the disease were identified. In addition, there were clusters of pneumonia incidents among persons in close contact with those infected. The disease was unusual in its severity and its progression in spite of the antibiotic treatment typical for the bacterial pathogens that are known to be commonly associated with atypical pneumonia. The present inventors were one of the groups involved in the investigation of these patients. All tests for identifying commonly recognized viruses and bacteria were negative in these patients. The disease was given the acronym Severe Acute Respiratory Syndrome ("SARS"). The etiologic agent responsible for this disease was not known until the isolation of hSARS virus from the SARS patients by the present inventors as disclosed herein. Namely, the present invention discloses a novel human virus that has been isolated and identified from the patients suffering from SARS. The invention is useful in both clinical and scientific research applications.

3. SUMMARY OF INVENTION

The present invention is based upon the inventor's isolation and identification of a novel virus causing Severe Acute Respiratory Syndrome in humans ("hSARS virus"). The virus was isolated from the patients suffering from SARS in the recent outbreak of severe atypical pneumonia in China. The isolated virus is an enveloped, single-stranded RNA virus of positive polarity which belongs to the order, Nidovirales, of the family, Coronaviridae. Accordingly, the invention relates to the isolated hSARS virus that
morphologically and phylogenetically relates to known members of *Coronaviridae*. In a specific embodiment, the isolated hSARS virus is that which was deposited with China Center for Type Culture Collection (CCTCC) on April 2, 2003 and accorded an accession number, CCTCC-V200303, as described in Section 7, *infra*. In another specific embodiment, the invention provides complete genomic sequence of the hSARS virus. In a preferred embodiment, the virus comprises a nucleotide sequence of SEQ ID NO:15. In another specific embodiment, the invention provides nucleic acids isolated from the virus. The virus preferably comprises a nucleotide sequence of SEQ ID NO:1, 11 and/or 13 in its genome. In a specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:1, a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof. In another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:11, a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:11, or a complement thereof. In yet another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:13, a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15, or a complement thereof. Furthermore, in another specific embodiment, the
invention provides isolated nucleic acid molecules which hybridize under stringent conditions, as defined herein, to a nucleic acid molecule having the sequence of SEQ ID NO:1, 11, 13, 15, 16, 240, 737, 1108, 1590 or 1965 or a complement thereof. In one embodiment, the invention provides an isolated nucleic acid molecule which is antisense to the coding strand of a nucleic acid of the invention. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:13, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15, or a complement thereof. The invention further provides proteins or polypeptides that are isolated from the hSARS virus, including viral proteins isolated from cells infected with the virus but not present in comparable uninfected cells. The invention further provides proteins or polypeptides of SEQ ID NOS:2, 12 and 14 and those shown in Figures 11 (SEQ ID NOS:17-239, 241-736 and 738-1107) and 12 (1109-1589, 1591-1964, 1966-2470). The polypeptides or the proteins of the present
invention preferably have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by the sequence of SEQ ID NO:1, 11, 13, 16, 240, 737, 1108, 1590 or 1965. In other embodiments, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15, or a complement thereof. In other embodiments, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) of Figures 11 (SEQ ID NOS:17-239, 241-736 and 738-1107) and 12 (SEQ ID NOS:1109-1589, 1591-1964 and 1966-2470).

In one aspect, the invention provides a method for propagating the hSARS virus in host cells comprising infecting the host cells with the isolated hSARS virus, culturing the host cells to allow the virus to multiply, and harvesting the resulting virions. Also provide by the present invention are host cells that are infected with the hSARS virus. In another aspect, the invention relates to the use of the isolated hSARS virus for diagnostic and therapeutic methods. In a specific embodiment, the invention provides a method of detecting in a biological sample an antibody immunospecific for the hSARS virus using the isolated hSARS virus or any proteins or polypeptides thereof. In another specific embodiment, the invention provides a method of screening for an antibody which immunospecifically binds and neutralizes hSARS. Such an antibody is useful for a passive immunization or immunotherapy of a subject infected with hSARS.

The invention further relates to the use of the sequence information of the isolated virus for diagnostic and therapeutic methods. In a specific embodiment, the invention provides nucleic acid molecules which are suitable for use as primers consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 11, 13, or 15, a complement thereof, or at least a portion of the nucleotide sequence thereof. In another specific embodiment, the invention provides nucleic acid molecules which are suitable for hybridization to hSARS nucleic acid, including, but not limited to, as PCR primers, Reverse Transcriptase primers,
probes for Southern analysis or other nucleic acid hybridization analysis for the detection of hSARS nucleic acids, e.g., consisting of or comprising the nucleotide sequence of SEQ ID NO: 1, 11, 13, or 15, a complement thereof, or a portion thereof. The invention further encompasses chimeric or recombinant viruses encoded in whole or in part by said nucleotide sequences.

The invention further provides antibodies that specifically bind a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO: 1, 11, 13, 16, 240, 737, 1108, 1590 or 1965, or a fragment thereof, or encoded by a nucleic acid comprising a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 1, 11, or 13, and/or any hSARS epitope, having one or more biological activities of a polypeptide of the invention. The invention further provides antibodies that specifically bind polypeptides of the invention encoded by the nucleotide sequence of SEQ ID NO: 15 or a complement thereof, or a fragment thereof. These polypeptides include those shown in Figures 11 (SEQ ID NOS: 17-239, 241-736 and 738-1107) and 12 (SEQ ID NOS: 1109-1589, 1591-1964 and 1966-2470). The invention further provides antibodies that specifically bind polypeptides of the invention encoded by a nucleic acid comprising a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 15, and/or any hSARS epitope, having one or more biological activities of a polypeptide of the invention. Such antibodies include, but are not limited to polyclonal, monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab')2 fragments, disulfide-linked Fvs, intrabodies and fragments containing either a VL or VH domain or even a complementary determining region (CDR) that specifically binds to a polypeptide of the invention.

In one embodiment, the invention provides methods for detecting the presence, activity or expression of the hSARS virus of the invention in a biological material, such as cells, blood, saliva, urine, and so forth. The increased or decreased activity or expression of the hSARS virus in a sample relative to a control sample can be determined by contacting the biological material with an agent which can detect directly or indirectly the presence, activity or expression of the hSARS virus. In a specific embodiment, the detecting agents are the antibodies or nucleic acid molecules of the present invention. Antibodies of the invention may also be used to treat SARS.
In another embodiment, the invention provides vaccine preparations, comprising the hSARS virus, including recombinant and chimeric forms of said virus, or protein subunits of the virus. In a specific embodiment, the vaccine preparations of the present invention comprise live but attenuated hSARS virus with or without adjuvants. In another specific embodiment, the vaccine preparations of the invention comprise an inactivated or killed hSARS virus. Such attenuated or inactivated viruses may be prepared by a series of passages of the virus through the host cells or by preparing recombinant or chimeric forms of virus. Accordingly, the present invention further provides methods of preparing recombinant or chimeric forms of hSARS. In another specific invention, the vaccine preparations of the present invention comprise a nucleic acid or fragment of the hSARS virus, e.g., the virus having accession no. CCTCC-V200303, or nucleic acid molecules having the sequence of SEQ ID NO. 1, 11, 13, or 15, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides isolated from or produced from nucleic acid of hSARS virus, for example, of deposit accession no. CCTCC-V200303. In a specific embodiment, the vaccine preparations comprise a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 11, 13, 16, 240, 737, 1108, 1590 or 1965, or a fragment thereof. In a specific embodiment, the vaccine preparations comprise polypeptides of the invention as shown in Figures 11 (SEQ ID NOS:17-239, 241-736 and 738-1107) and 12 (SEQ ID NOS:1109-1589, 1591-1964 and 1966-2470) or encoded by the nucleotide sequence of SEQ ID NO:15, or a fragment thereof. Furthermore, the present invention provides methods for treating, ameliorating, managing or preventing SARS by administering the vaccine preparations or antibodies of the present invention alone or in combination with adjuvants, or other pharmaceutically acceptable excipients.

In another aspect, the present invention provides pharmaceutical compositions comprising anti-viral agents of the present invention and a pharmaceutically acceptable carrier. In a specific embodiment, the anti-viral agent of the invention is an antibody that immunospecifically binds hSARS virus or any hSARS epitope. In another specific embodiment, the anti-viral agent is a polypeptide or protein of the present invention or nucleic acid molecule of the invention. The invention also provides kits containing a pharmaceutical composition of the present invention.
3.1 Definitions

The term "an antibody or an antibody fragment that immunospecifically binds a polypeptide of the invention" as used herein refers to an antibody or a fragment thereof that immunospecifically binds to the polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 11, 13 or 15, or a fragment thereof, and does not non-specifically bind to other polypeptides. An antibody or a fragment thereof that immunospecifically binds to the polypeptide of the invention may cross-react with other antigens. Preferably, an antibody or a fragment thereof that immunospecifically binds to a polypeptide of the invention does not cross-react with other antigens. An antibody or a fragment thereof that immunospecifically binds to the polypeptide of the invention, can be identified by, for example, immunoassays or other techniques known to those skilled in the art.

An "isolated" or "purified" peptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of a polypeptide/protein in which the polypeptide/protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, a polypeptide/protein that is substantially free of cellular material includes preparations of the polypeptide/protein having less than about 30%, 20%, 10%, 5%, 2.5%, or 1%, (by dry weight) of contaminating protein. When the polypeptide/protein is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When polypeptide/protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly, such preparations of the polypeptide/protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than polypeptide/protein fragment of interest. In a preferred embodiment of the present invention, polypeptides/proteins are isolated or purified.

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be
substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In a preferred embodiment of the invention, nucleic acid molecules encoding polypeptides/proteins of the invention are isolated or purified. The term "isolated" nucleic acid molecule does not include a nucleic acid that is a member of a library that has not been purified away from other library clones containing other nucleic acid molecules.

The term “portion” or “fragment” as used herein refers to a fragment of a nucleic acid molecule containing at least about 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000, 16000, 17000, 18000, 19000, 20000, 21000, 22000, 23000, 24000, 25000, 26000, 27000, 28000, 29000, or more contiguous nucleic acids in length of the relevant nucleic acid molecule and having at least one functional feature of the nucleic acid molecule (or the encoded protein has one functional feature of the protein encoded by the nucleic acid molecule); or a fragment of a protein or a polypeptide containing at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4100, 4200, 4300, 4350, 4360, 4370, 4380 amino acid residues in length of the relevant protein or polypeptide and having at least one functional feature of the protein or polypeptide.

The term “having a biological activity of the protein” or “having biological activities of the polypeptides of the invention” refers to the characteristics of the polypeptides or proteins having a common biological activity similar or identical structural domain and/or having sufficient amino acid identity to the polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 11, 13, 15, 16, 240, 737, 1108, 1590 or 1965. Such common biological activities of the polypeptides of the invention include antigenicity and immunogenicity.

The term "under stringent condition" refers to hybridization and washing conditions under which nucleotide sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to each other remain hybridized to each other. Such hybridization conditions are described in, for example but not limited to, Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.; Basic
Methods in Molecular Biology, Elsevier Science Publishing Co., Inc., N.Y. (1986), pp. 75-78, and 84-87; and Molecular Cloning, Cold Spring Harbor Laboratory, N.Y. (1982), pp. 387-389, and are well known to those skilled in the art. A preferred, non-limiting example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC), 0.5% SDS at about 68°C followed by one or more washes in 2X SSC, 0.5% SDS at room temperature. Another preferred, non-limiting example of stringent hybridization conditions is hybridization in 6X SSC at about 45°C followed by one or more washes in 0.2X SSC, 0.1% SDS at about 50-65°C.

The term “variant” as used herein refers either to a naturally occurring genetic mutant of hSARS or a recombinantly prepared variation of hSARS each of which contain one or more mutations in its genome compared to the hSARS of CCTCC-V200303. The term “variant” may also refers either to a naturally occurring variation of a given peptide or a recombinantly prepared variation of a given peptide or protein in which one or more amino acid residues have been modified by amino acid substitution, addition, or deletion.

4. DESCRIPTION OF THE FIGURES

Figure 1 shows a partial DNA sequence (SEQ ID NO:1) and its deduced amino acid sequence (SEQ ID NO:2) obtained from the SARS virus that has 57% homology to the RNA-dependent RNA polymerase protein of known *Coronaviruses*.

Figure 2 shows an electron micrograph of the novel hSARS virus that has similar morphological characteristics of coronaviruses.

Figure 3 shows an immunofluorescent staining for IgG antibodies that are specifically bound to the FrHK-4 cells infected with the novel human respiratory virus of *Coronaviridae*.

Figure 4 shows an electron micrograph of ultra-centrifuged deposit of hSARS virus that was grown in the cell culture and negatively stained with 3% potassium phosphotungstate at pH 7.0.

Figure 5A shows a thin-section electron micrograph of lung biopsy of a patient with SARS; and Figure 5B shows a thin section electron micrograph of hSARS-infected cells.

Figure 6 shows the result of phylogenetic analysis for the partial protein sequence (215 amino acids; SEQ ID NO:2) of the hSARS virus (GenBank accession number
AY268070). The phylogenetic tree is constructed by the neighbor-joining method. The horizontal-line distance represents the number of sites at which the two sequences compared are different. Bootstrap values are deducted from 500 replicates.

Figure 7A shows an amplification plot of fluorescence intensity against the PCR cycle in a real-time quantitative PCR assay that can detect a hSARS virus in samples quantitatively. The copy numbers of input plasmid DNA in the reactions are indicated. The X-axis denotes the cycle number of a quantitative PCR assay and the Y-axis denotes the fluorescence intensity (FI) over the background. Figure 7B shows the result of a melting curve analysis of PCR products from clinical samples. Signals from positive (+ve) samples, negative (-ve) samples and water control (water) are indicated. The X-axis denotes the temperature (°C) and the Y-axis denotes the fluorescence intensity (FI) over the background.

Figure 8 shows another partial DNA sequence (SEQ ID NO:11) and its deduced amino acid sequence (SEQ ID NO:12) obtained from the SARS virus.

Figure 9 shows yet another partial DNA sequence (SEQ ID NO:13) and its deduced amino acid sequence (SEQ ID NO:14) obtained from the SARS virus.

Figure 10 shows the entire genomic DNA sequence (SEQ ID NO:15) of the SARS virus.

Figure 11 shows the deduced amino acid sequences obtained from SEQ ID NO:15 in three frames (see SEQ ID NOS:16, 240 and 737). An asterisk (*) indicates a stop codon which marks the end of a peptide. The first-frame amino acid sequences: SEQ ID NOS:17-239; the second-frame amino acid sequences: SEQ ID NOS:241-736; and the third-frame amino acid sequences: SEQ ID NO:738-1107.

Figure 12 shows the deduced amino acid sequences obtained from the complement of SEQ ID NO:15 in three frames (see SEQ ID NOS:1108, 1590 and 1965). An asterisk (*) indicates a stop codon which marks the end of a peptide. The first-frame amino acid sequences: SEQ ID NOS:1109-1589; the second-frame amino acid sequences: SEQ ID NOS:1591-1964; and the third-frame amino acid sequences: SEQ ID NO:1966-2470.

5. DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to the isolated hSARS virus that morphologically and phylogenetically relates to known *Coronaviruses*. In a specific embodiment, the isolated hSARS virus is that of CCTCC-V200303. In another specific embodiment, the virus comprises a nucleotide sequence of SEQ ID NO:1, 11, 13, and/or 15. In a specific embodiment, the present invention provides isolated nucleic acid molecules of the hSARS virus, comprising, or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:1, 11, 13, and/or 15, a complement thereof or a portion thereof. In another specific embodiment, the invention provides isolated nucleic acid molecules which hybridize under stringent conditions, as defined herein, to a nucleic acid molecule having the sequence of SEQ ID NO:1, 11, 13, or 15, or specific genes of known member of *Coronaviridae*, or a complement thereof. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:11, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:13, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15, or a complement thereof. The polypeptides include
those shown in Figures 11 (SEQ ID NOS: 17-239, 241-736 and 738-1107) and 12 (SEQ ID NOS: 1109-1589, 1591-1964 and 1966-2470). The polypeptides or the proteins of the present invention preferably have one or more biological activities of the proteins encoded by the sequence of SEQ ID NO: 1, 11, 13, 15, or the native viral proteins containing the amino acid sequences encoded by the sequence of SEQ ID NO: 1, 11, 13, or 15, or those shown in Figures 11 (SEQ ID NOS: 17-239, 241-736 and 738-1107) and 12 (SEQ ID NOS: 1109-1589, 1591-1964 and 1966-2470).

The present invention also relates to a method for propagating the hSARS virus in host cells.

The invention further relates to the use of the sequence information of the isolated virus for diagnostic and therapeutic methods. In a specific embodiment, the invention provides the entire nucleotide sequence of hSARS virus, CCTCC-V200303, SEQ ID NO: 15, or fragments, or complement thereof. Furthermore, the present invention relates to a nucleic acid molecule that hybridizes any portion of the genome of the hSARS virus, CCTCC-V200303, SEQ ID NO: 15, under the stringent conditions. In a specific embodiment, the invention provides nucleic acid molecules which are suitable for use as primers consisting of or comprising the nucleotide sequence of SEQ ID NO: 1, 11, 13, or 15, or a complement thereof, or a portion thereof. In a non-limiting embodiment, the invention provides the primers consisting of or comprising the nucleotide sequence of SEQ ID NOS: 3 and/or 4. In another specific embodiment, the invention provides nucleic acid molecules which are suitable for use as hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention, consisting of or comprising the nucleotide sequence of SEQ ID NO: 1, 11, 13, or 15, a complement thereof, or a portion thereof. The invention further encompasses chimeric or recombinant viruses or viral proteins encoded by said nucleotide sequences.

The invention further provides antibodies that specifically bind a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO: 1, 11, 13, 16, 240, 737, 1108, 1590 or 1965, or a fragment thereof, or any hSARS epitope. The invention further provides antibodies that specifically bind the polypeptides of the invention encoded by the nucleotide sequence of SEQ ID NO: 15, or a fragment thereof, or any hSARS epitope. Such antibodies include, but are not limited to polyclonal, monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab')2 fragments,
disulfide-linked Fvs, intrabodies and fragments containing either a VL or VH domain or even a complementary determining region (CDR) that specifically binds to a polypeptide of the invention.

In one embodiment, the invention provides methods for detecting the presence, activity or expression of the hSARS virus of the invention in a biological material, such as cells, blood, saliva, urine, sputum, nasopharyngeal aspirates, and so forth. The presence of the hSARS virus in a sample can be determined by contacting the biological material with an agent which can detect directly or indirectly the presence of the hSARS virus. In a specific embodiment, the detection agents are the antibodies of the present invention. In another embodiment, the detection agent is a nucleic acid of the present invention.

In another embodiment, the invention provides vaccine preparations comprising the hSARS virus, including recombinant and chimeric forms of said virus, or subunits of the virus. In a specific embodiment, the vaccine preparations comprise live but attenuated hSARS virus with or without pharmaceutically acceptable carriers, including adjuvants. In another specific embodiment, the vaccine preparations comprise an inactivated or killed hSARS virus with or without pharmaceutically acceptable carriers, including adjuvants.

The present invention further provides methods of preparing recombinant or chimeric forms of hSARS. In another specific invention, the vaccine preparations of the present invention comprise one or more nucleic acid molecules comprising or consisting of the sequence of SEQ ID NO. 1, 11, 13, and/or, 15, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides of the invention encoded by a nucleotide sequence comprising or consisting of the nucleotide sequence of SEQ ID NO:1, 11, 13, 16, 240, 737, 1108, 1590 and/or 1965, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides of the invention encoded by a nucleotide sequence comprising or consisting of the nucleotide sequence of SEQ ID NO:15, or a fragment thereof. Furthermore, the present invention provides methods for treating, ameliorating, managing, or preventing SARS by administering the vaccine preparations or antibodies of the present invention alone or in combination with antivirals [e.g., amantadine, rimantadine, gancyclovir, acyclovir, ribavirin, penciclovir, oseltamivir, foscarnet zidovudine (AZT), didanosine (ddI), lamivudine (3TC), zalcitabine (ddC), stavudine (d4T), nevirapine, delavirdine, indinavir, ritonavir, vidarabine, nelfinavir, saquinavir, relenza, tamiflu,
pleconaril, interferons, etc.), steroids and corticosteroids such as prednisone, cortisone, fluticasone and glucocorticoid, antibiotics, analgesics, bronchodilators, or other treatments for respiratory and/or viral infections.

Furthermore, the present invention provides pharmaceutical compositions comprising anti-viral agents of the present invention and a pharmaceutically acceptable carrier. The present invention also provides kits comprising pharmaceutical compositions of the present invention.

In another aspect, the present invention provides methods for screening anti-viral agents that inhibit the infectivity or replication of hSARS virus or variants thereof.

5.1 Recombinant and Chimeric hSARS Viruses

The present invention encompasses recombinant or chimeric viruses encoded by viral vectors derived from the genome of hSARS virus or natural variants thereof. In a specific embodiment, a recombinant virus is one derived from the hSARS virus of deposit accession no. CCTCC-V200303. In a specific embodiment, the virus has a nucleotide sequence of SEQ ID NO:15. In another specific embodiment, a recombinant virus is one derived from a natural variant of hSARS virus. A natural variant of hSARS has a sequence that is different from the genomic sequence (SEQ ID NO:15) of the hSARS virus, CCTCC-V200303, due to one or more naturally occurred mutations, including, but not limited to, point mutations, rearrangements, insertions, deletions etc., to the genomic sequence that may or may not result in a phenotypic change. In accordance with the present invention, a viral vector which is derived from the genome of the hSARS virus, CCTCC-V200303, is one that contains a nucleic acid sequence that encodes at least a part of one ORF of the hSARS virus. In a specific embodiment, the ORF comprises or consists of a nucleotide sequence of SEQ ID NO:1, 11 or 13, or a fragment thereof. In a specific embodiment, there are more than one ORF within the nucleotide sequence of SEQ ID NO:15 or a complement thereof, as shown in Figures 11 (SEQ ID NOS:16, 240 and 737) and 12 (SEQ ID NOS:1108, 1590 and 1965), or a fragment thereof. In another embodiment, the polypeptide encoded by the ORF comprises or consists of an amino acid sequence of SEQ ID NO:2, 12, or 14, or a fragment thereof, or shown in Figures 11 (SEQ ID NOS:17-239, 241-736 and 738-1107) and 12 (SEQ ID NOS:1109-1589, 1591-1964 and 1966-2470), or a fragment thereof. In
accordance with the present invention these viral vectors may or may not include nucleic acids that are non-native to the viral genome.

In another specific embodiment, a chimeric virus of the invention is a recombinant hSARS virus which further comprises a heterologous nucleotide sequence. In accordance with the invention, a chimeric virus may be encoded by a nucleotide sequence in which heterologous nucleotide sequences have been added to the genome or in which endogenous or native nucleotide sequences have been replaced with heterologous nucleotide sequences. According to the present invention, the chimeric viruses are encoded by the viral vectors of the invention which further comprise a heterologous nucleotide sequence. In accordance with the present invention a chimeric virus is encoded by a viral vector that may or may not include nucleic acids that are non-native to the viral genome. In accordance with the invention a chimeric virus is encoded by a viral vector to which heterologous nucleotide sequences have been added, inserted or substituted for native or non-native sequences. In accordance with the present invention, the chimeric virus may be encoded by nucleotide sequences derived from different strains or variants of hSARS virus. In particular, the chimeric virus is encoded by nucleotide sequences that encode antigenic polypeptides derived from different strains or variants of hSARS virus.

A chimeric virus may be of particular use for the generation of recombinant vaccines protecting against two or more viruses (Tao et al., J. Virol. 72, 2955-2961; Durbin et al., 2000, J.Virol. 74, 6821-6831; Skiadopoulos et al., 1998, J. Virol. 72, 1762-1768 (1998); Teng et al., 2000, J.Virol. 74, 9317-9321). For example, it can be envisaged that a virus vector derived from the hSARS virus expressing one or more proteins of variants of hSARS virus, or vice versa, will protect a subject vaccinated with such vector against infections by both the native hSARS and the variant. Attenuated and replication-defective viruses may be of use for vaccination purposes with live vaccines as has been suggested for other viruses. (See, PCT WO 02/057302, at pp. 6 and 23, incorporated by reference herein).

In accordance with the present invention the heterologous sequence to be incorporated into the viral vectors encoding the recombinant or chimeric viruses of the invention include sequences obtained or derived from different strains or variants of hSARS.

In certain embodiments, the chimeric or recombinant viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more sequences, intergenic regions, termini sequences, or portions or entire ORF have been substituted with a heterologous or non-native sequence. In certain embodiments of the invention, the
chimeric viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more heterologous sequences have been inserted or added to the vector.

The selection of the viral vector may depend on the species of the subject that is to be treated or protected from a viral infection. If the subject is human, then an attenuated hSARS virus can be used to provide the antigenic sequences.

In accordance with the present invention, the viral vectors can be engineered to provide antigenic sequences which confer protection against infection by the hSARS and natural variants thereof. The viral vectors may be engineered to provide one, two, three or more antigenic sequences. In accordance with the present invention the antigenic sequences may be derived from the same virus, from different strains or variants of the same type of virus, or from different viruses.

The expression products and/or recombinant or chimeric virions obtained in accordance with the invention may advantageously be utilized in vaccine formulations. The expression products and chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral and bacterial antigens, tumor antigens, allergen antigens, and auto antigens involved in autoimmune disorders. In particular, the chimeric virions of the present invention may be engineered to create vaccines for the protection of a subject from infections with hSARS virus and variants thereof.

In certain embodiments, the expression products and recombinant or chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral antigens, tumor antigens and autoantigens involved in autoimmune disorders. One way to achieve this goal involves modifying existing hSARS genes to contain foreign sequences in their respective external domains. Where the heterologous sequences are epitopes or antigens of pathogens, these chimeric viruses may be used to induce a protective immune response against the disease agent from which these determinants are derived.

Thus, the present invention relates to the use of viral vectors and recombinant or chimeric viruses to formulate vaccines against a broad range of viruses and/or antigens. The present invention also encompasses recombinant viruses comprising a viral vector derived from the hSARS or variants thereof which contains sequences which result in a virus having a phenotype more suitable for use in vaccine formulations, e.g., attenuated
phenotype or enhanced antigenicity. The mutations and modifications can be in coding regions, in intergenic regions and in the leader and trailer sequences of the virus.

The invention provides a host cell comprising a nucleic acid or a vector according to the invention. Plasmid or viral vectors containing the polymerase components of hSARS virus are generated in prokaryotic cells for the expression of the components in relevant cell types (bacteria, insect cells, eukaryotic cells). Plasmid or viral vectors containing full-length or partial copies of the hSARS genome will be generated in prokaryotic cells for the expression of viral nucleic acids in-vitro or in-vivo. The latter vectors may contain other viral sequences for the generation of chimeric viruses or chimeric virus proteins, may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses. In addition, the present invention provides a host cell infected with hSARS virus, for example, of deposit no. CCTCC-V200303.

Infectious copies of hSARS (being wild type, attenuated, replication-defective or chimeric) can be produced upon co-expression of the polymerase components according to the state-of-the-art technologies described above.

In addition, eukaryotic cells, transiently or stably expressing one or more full-length or partial hSARS proteins can be used. Such cells can be made by transfection (proteins or nucleic acid vectors), infection (viral vectors) or transduction (viral vectors) and may be useful for complementation of mentioned wild type, attenuated, replication-defective or chimeric viruses.

The viral vectors and chimeric viruses of the present invention may be used to modulate a subject’s immune system by stimulating a humoral immune response, a cellular immune response or by stimulating tolerance to an antigen. As used herein, a subject means: humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, avian species and rodents.

5.2 Formulation of Vaccines and Antivirals

In a preferred embodiment, the invention provides a proteinaceous molecule or hSARS virus specific viral protein or functional fragment thereof encoded by a nucleic acid according to the invention. Useful proteinaceous molecules are for example derived from any of the genes or genomic fragments derivable from the virus according to the invention, including envelop protein (E protein), integral membrane protein (M protein), spike protein.
(S protein), nucleocapsid protein (N protein), hemagglutinin esterase (HE protein), and RNA-dependent RNA polymerase. Such molecules, or antigenic fragments thereof, as provided herein, are for example useful in diagnostic methods or kits and in pharmaceutical compositions such as subunit vaccines. Particularly useful are polypeptides encoded by the nucleotide sequence of SEQ ID NO: 1, 11, 13, or 15, or as shown in Figures 11 (SEQ ID NOS: 17-239, 241-736 and 738-1107) and 12 (SEQ ID NOS: 1109-1589, 1591-1964 and 1966-2470), or antigenic fragments thereof for inclusion as antigen or subunit immunogen, but inactivated whole virus can also be used. Particularly useful are also those proteinaceous substances that are encoded by recombinant nucleic acid fragments of the hSARS genome, of course preferred are those that are within the preferred bounds and metes of ORFs, in particular, for eliciting hSARS specific antibody or T cell responses, whether in vivo (e.g. for protective or therapeutic purposes or for providing diagnostic antibodies) or in vitro (e.g. by phage display technology or another technique useful for generating synthetic antibodies).

The invention provides vaccine formulations for the prevention and treatment of infections with hSARS virus. In certain embodiments, the vaccine of the invention comprises recombinant and chimeric viruses of the hSARS virus. In certain embodiments, the virus is attenuated.

In another embodiment of this aspect of the invention, inactivated vaccine formulations may be prepared using conventional techniques to "kill" the chimeric viruses. Inactivated vaccines are "dead" in the sense that their infectivity has been destroyed. Ideally, the infectivity of the virus is destroyed without affecting its immunogenicity. In order to prepare inactivated vaccines, the chimeric virus may be grown in cell culture or in the allantois of the chick embryo, purified by zonal ultracentrifugation, inactivated by formaldehyde or β-propiolactone, and pooled. The resulting vaccine is usually inoculated intramuscularly.

Inactivated viruses may be formulated with a suitable adjuvant in order to enhance the immunological response. Such adjuvants may include but are not limited to mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols, polyanions; peptides; oil emulsions; and potentially useful human adjuvants such as BCG and Corynebacterium parvum.
In another aspect, the present invention also provides DNA vaccine formulations comprising a nucleic acid or fragment of the hSARS virus, e.g., the virus having accession no. CCTCC-V200303, or nucleic acid molecules having the sequence of SEQ ID NO: 1, 11, 13, or 15, or a fragment thereof. In another specific embodiment, the DNA vaccine formulations of the present invention comprises a nucleic acid or fragment thereof encoding the antibodies which immunospecifically binds hSARS viruses. In DNA vaccine formulations, a vaccine DNA comprises a viral vector, such as that derived from the hSARS virus, bacterial plasmid, or other expression vector, bearing an insert comprising a nucleic acid molecule of the present invention operably linked to one or more control elements, thereby allowing expression of the vaccinating proteins encoded by said nucleic acid molecule in a vaccinated subject. Such vectors can be prepared by recombinant DNA technology as recombinant or chimeric viral vectors carrying a nucleic acid molecule of the present invention (see also Section 5.1, supra).

Various heterologous vectors are described for DNA vaccinations against viral infections. For example, the vectors described in the following references may be used to express hSARS sequences instead of the sequences of the viruses or other pathogens described; in particular, vectors described for hepatitis B virus (Michel, M.L. et al., 1995, DAN-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans, Proc. Natl. Aca. Sci. USA 92:5307-5311; Davis, H.L. et al., 1993, DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody, Human Molec. Genetics 2:1847-1851), HIV virus (Wang, B. et al., 1993, Gene inoculation generates immune responses against human immunodeficiency virus type 1, Proc. Natl. Acad. Sci. USA 90:4156-4160; Lu, S. et al., 1996, Simian immunodeficiency virus DNA vaccine trial in macques, J. Virol. 70:3978-3991; Letvin, N.L. et al., 1997, Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination, Proc Natl Acad Sci USA 94(17):9378-83), and influenza viruses (Robinson, HL et al., 1993, Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA, Vaccine 11:957-960; Ulmer, J.B. et al.,

Heterologous protection against influenza by injection of DNA encoding a viral protein, Science 259:1745-1749), as well as bacterial infections, such as tuberculosis (Tascon, R.E. et al., 1996, Vaccination against tuberculosis by DNA injection, Nature Med. 2:888-892;


5.3 Attenuation of hSARS Virus or Variants Thereof

The hSARS virus or variants thereof of the invention can be genetically engineered to exhibit an attenuated phenotype. In particular, the viruses of the invention exhibit an attenuated phenotype in a subject to which the virus is administered as a vaccine.

Attenuation can be achieved by any method known to a skilled artisan. Without being bound by theory, the attenuated phenotype of the viruses of the invention can be caused, e.g., by using a virus that naturally does not replicate well in an intended host species, for
example, by reduced replication of the viral genome, by reduced ability of the virus to infect a host cell, or by reduced ability of the viral proteins to assemble to an infectious viral particle relative to the wild type strain of the virus.

The attenuated phenotypes of hSARS virus or variants thereof can be tested by any method known to the artisan. A candidate virus can, for example, be tested for its ability to infect a host or for the rate of replication in a cell culture system. In certain embodiments, growth curves at different temperatures are used to test the attenuated phenotype of the virus. For example, an attenuated virus is able to grow at 35°C, but not at 39°C or 40°C. In certain embodiments, different cell lines can be used to evaluate the attenuated phenotype of the virus. For example, an attenuated virus may only be able to grow in monkey cell lines but not the human cell lines, or the achievable virus titers in different cell lines are different for the attenuated virus. In certain embodiments, viral replication in the respiratory tract of a small animal model, including but not limited to, hamsters, cotton rats, mice and guinea pigs, is used to evaluate the attenuated phenotypes of the virus. In other embodiments, the immune response induced by the virus, including but not limited to, the antibody titers (e.g., assayed by plaque reduction neutralization assay or ELISA) is used to evaluate the attenuated phenotypes of the virus. In a specific embodiment, the plaque reduction neutralization assay or ELISA is carried out at a low dose. In certain embodiments, the ability of the hSARS virus to elicit pathological symptoms in an animal model can be tested. A reduced ability of the virus to elicit pathological symptoms in an animal model system is indicative of its attenuated phenotype. In a specific embodiment, the candidate viruses are tested in a monkey model for nasal infection, indicated by mucous production.

The viruses of the invention can be attenuated such that one or more of the functional characteristics of the virus are impaired. In certain embodiments, attenuation is measured in comparison to the wild type strain of the virus from which the attenuated virus is derived. In other embodiments, attenuation is determined by comparing the growth of an attenuated virus in different host systems. Thus, for a non-limiting example, hSARS virus or a variant thereof is said to be attenuated when grown in a human host if the growth of the hSARS or variant thereof in the human host is reduced compared to the non-attenuated hSARS or variant thereof.

In certain embodiments, the attenuated virus of the invention is capable of infecting a host, is capable of replicating in a host such that infectious viral particles are produced. In comparison to the wild type strain, however, the attenuated strain grows to lower titers or
grows more slowly. Any technique known to the skilled artisan can be used to determine the growth curve of the attenuated virus and compare it to the growth curve of the wild type virus.

In certain embodiments, the attenuated virus of the invention (e.g., a recombinant or chimeric hSARS) cannot replicate in human cells as well as the wild type virus (e.g., wild type hSARS) does. However, the attenuated virus can replicate well in a cell line that lack interferon functions, such as Vero cells.

In other embodiments, the attenuated virus of the invention is capable of infecting a host, of replicating in the host, and of causing proteins of the virus of the invention to be inserted into the cytoplasmic membrane, but the attenuated virus does not cause the host to produce new infectious viral particles. In certain embodiments, the attenuated virus infects the host, replicates in the host, and causes viral proteins to be inserted in the cytoplasmic membrane of the host with the same efficiency as the wild type hSARS. In other embodiments, the ability of the attenuated virus to cause viral proteins to be inserted into the cytoplasmic membrane into the host cell is reduced compared to the wild type virus. In certain embodiments, the ability of the attenuated hSARS virus to replicate in the host is reduced compared to the wild type virus. Any technique known to the skilled artisan can be used to determine whether a virus is capable of infecting a mammalian cell, of replicating within the host, and of causing viral proteins to be inserted into the cytoplasmic membrane of the host.

In certain embodiments, the attenuated virus of the invention is capable of infecting a host. In contrast to the wild type hSARS, however, the attenuated hSARS cannot be replicated in the host. In a specific embodiment, the attenuated hSARS virus can infect a host and can cause the host to insert viral proteins in its cytoplasmic membranes, but the attenuated virus is incapable of being replicated in the host. Any method known to the skilled artisan can be used to test whether the attenuated hSARS has infected the host and has caused the host to insert viral proteins in its cytoplasmic membranes.

In certain embodiments, the ability of the attenuated virus to infect a host is reduced compared to the ability of the wild type virus to infect the same host. Any technique known to the skilled artisan can be used to determine whether a virus is capable of infecting a host.

In certain embodiments, mutations (e.g., missense mutations) are introduced into the genome of the virus, for example, into the sequence of SEQ ID NO:1, 11, 13, or 15, or to generate a virus with an attenuated phenotype. Mutations (e.g., missense mutations) can be
introduced into the structural genes and/or regulatory genes of the hSARS. Mutations can be additions, substitutions, deletions, or combinations thereof. Such variant of hSARS can be screened for a predicted functionality, such as infectivity, replication ability, protein synthesis ability, assembling ability, as well as cytopathic effect in cell cultures. In a specific embodiment, the missense mutation is a cold-sensitive mutation. In another embodiment, the missense mutation is a heat-sensitive mutation. In another embodiment, the missense mutation prevents a normal processing or cleavage of the viral proteins.

In other embodiments, deletions are introduced into the genome of the hSARS virus, which result in the attenuation of the virus.

In certain embodiments, attenuation of the virus is achieved by replacing a gene of the wild type virus with a gene of a virus of a different species, of a different subgroup, or of a different variant. In another aspect, attenuation of the virus is achieved by replacing one or more specific domains of a protein of the wild type virus with domains derived from the corresponding protein of a virus of a different species. In certain other embodiments, attenuation of the virus is achieved by deleting one or more specific domains of a protein of the wild type virus.

When a live attenuated vaccine is used, its safety must also be considered. The vaccine must not cause disease. Any techniques known in the art that can make a vaccine safe may be used in the present invention. In addition to attenuation techniques, other techniques may be used. One non-limiting example is to use a soluble heterologous gene that cannot be incorporated into the virion membrane. For example, a single copy of the soluble version of a viral transmembrane protein lacking the transmembrane and cytosolic domains thereof, can be used.

Various assays can be used to test the safety of a vaccine. For example, sucrose gradients and neutralization assays can be used to test the safety. A sucrose gradient assay can be used to determine whether a heterologous protein is inserted in a virion. If the heterologous protein is inserted in the virion, the virion should be tested for its ability to cause symptoms in an appropriate animal model since the virus may have acquired new, possibly pathological, properties.

5.4 Adjuvants and Carrier Molecules
hSARS-associated antigens are administered with one or more adjuvants. In one embodiment, the hSARS-associated antigen is administered together with a mineral salt adjuvants or mineral salt gel adjuvant. Such mineral salt and mineral salt gel adjuvants include, but are not limited to, aluminum hydroxide (ALHYDROGEL, REHYDRAGEL), aluminum phosphate gel, aluminum hydroxyphosphate (ADJU-PHOS), and calcium phosphate.

In another embodiment, hSARS-associated antigen is administered with an immunostimulatory adjuvant. Such class of adjuvants, include, but are not limited to, cytokines (e.g., interleukin-2, interleukin-7, interleukin-12, granulocyte-macrophage colony stimulating factor (GM-CSF), interferon-γ interleukin-1β (IL-1β), and IL-1β peptide or Sclavo Peptide), cytokine-containing liposomes, triterpenoid glycosides or saponins (e.g., QuilA and QS-21, also sold under the trademark STIMULON, ISCOPREP), Muramyl Dipeptide (MDP) derivatives, such as N-acetyl-muramyl-L-threonyl-D-isoglutamine (Threonyl-MDP, sold under the trademark TERMURTIDE), GMDP, N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxy phosphoryloxy)-ethyamine, muramyl tripeptide phosphatidylethanolamine (MTP-PE), unmethylated CpG dinucleotides and oligonucleotides, such as bacterial DNA and fragments thereof, LPS, monophosphoryl Lipid A (3D-MLA sold under the trademark MPL), and polyphosphazenes.

In another embodiment, the adjuvant used is a particular adjuvant, including, but not limited to, emulsions, e.g., Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, squalene or squalane oil-in-water adjuvant formulations, such as SAF and MF59, e.g., prepared with block-copolymers, such as L-121 (polyoxypropylene/polyoxyethylene) sold under the trademark PLURONIC L-121, Liposomes, Virosomes, cochleates, and immune stimulating complex, which is sold under the trademark ISCOM.

In another embodiment, a microparticulate adjuvant is used. Microparticulate adjuvants include, but are not limited to biodegradable and biocompatible polyesters, homopolymers of lactic acid (PLA) and glycolic acid (PGA), poly(lactide-co-glycolides) (PLGA) microparticles, polymers that self-associate into particulates (poloxamer particles), soluble polymers (polyphosphazenes), and virus-like particles (VLPs) such as recombinant protein particulates, e.g., hepatitis B surface antigen (HbsAg).
Yet another class of adjuvants that may be used include mucosal adjuvants, including but not limited to heat-labile enterotoxin from *Escherichia coli* (LT), cholera holotoxin (CT) and cholera Toxin B Subunit (CTB) from *Vibrio cholerae*, mutant toxins (*e.g.*, LTK63 and LTR72), microparticles, and polymerized liposomes.

In other embodiments, any of the above classes of adjuvants may be used in combination with each other or with other adjuvants. For example, non-limiting examples of combination adjuvant preparations that can be used to administer the hSARS-associated antigens of the invention include liposomes containing immunostimulatory protein, cytokines, or T-cell and/or B-cell peptides, or microbes with or without entrapped IL-2 or microparticles containing enterotoxin. Other adjuvants known in the art are also included within the scope of the invention (see *Vaccine Design: The Subunit and Adjuvant Approach*, Chap. 7, Michael F. Powell and Mark J. Newman (eds.), Plenum Press, New York, 1995, which is incorporated herein in its entirety).

The effectiveness of an adjuvant may be determined by measuring the induction of antibodies directed against an immunogenic polypeptide containing a hSARS polypeptide epitope, the antibodies resulting from administration of this polypeptide in vaccines which are also comprised of the various adjuvants.

The polypeptides may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid additional salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

Many methods may be used to introduce the vaccine formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, *e.g.*, using a bifurcated needle).
The patient to which the vaccine is administered is preferably a mammal, most preferably a human, but can also be a non-human animal including but not limited to cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats.

5.5 Preparation of Antibodies

Antibodies which specifically recognize a polypeptide of the invention, such as, but not limited to, polypeptides comprising the sequence of SEQ ID NO:2, 12, and 14, and polypeptides as shown in Figures 11 (SEQ ID NOS:17-239, 241-736 and 738-1107) and 12 (SEQ ID NOS:1109-1589, 1591-1964 and 1966-2470), or hSARS epitope or antigen-binding fragments thereof can be used for detecting, screening, and isolating the polypeptide of the invention or fragments thereof, or similar sequences that might encode similar enzymes from the other organisms. For example, in one specific embodiment, an antibody which immunospecifically binds hSARS epitope, or a fragment thereof, can be used for various in vitro detection assays, including enzyme-linked immunosorbent assays (ELISA), radioimmunoassays, Western blot, etc., for the detection of a polypeptide of the invention or, preferably, hSARS, in samples, for example, a biological material, including cells, cell culture media (e.g., bacterial cell culture media, mammalian cell culture media, insect cell culture media, yeast cell culture media, etc.), blood, plasma, serum, tissues, sputum, naseopharyngeal aspirates, etc.

Antibodies specific for a polypeptide of the invention or any epitope of hSARS may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest, for example, the hSARS virus from deposit no. CCTCC-V200303, or comprises a nucleotide sequence of SEQ ID NO:15, can be produced by various procedures well known in the art. For example, an antigen can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc., to induce the production of antisera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete) adjuvant, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful adjuvants for humans such as BCG (Bacille Calmette-Guerin) and Corynebacterium parvum. Such adjuvants are also well known in the art.
Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: Monoclonal Antibodies and T-Cell Hybridomas, pp. 563-681 (Elsevier, N.Y., 1981) (both of which are incorporated by reference in their entireties). The term “monoclonal antibody” as used herein is not limited to antibodies produced through hybridoma technology. The term “monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art. In a non-limiting example, mice can be immunized with an antigen of interest or a cell expressing such an antigen. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells. Hybridomas are selected and cloned by limiting dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding the antigen. Ascites fluid, which generally contains high levels of antibodies, can be generated by inoculating mice intraperitoneally with positive hybridoma clones.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')2 fragments may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). F(ab')2 fragments contain the complete light chain, and the variable region, the CH1 region and the hinge region of the heavy chain.

The antibodies of the invention or fragments thereof can be also produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

The nucleotide sequence encoding an antibody may be obtained from any information available to those skilled in the art (i.e., from Genbank, the literature, or by
routine cloning and sequence analysis). If a clone containing a nucleic acid encoding a particular antibody or an epitope-binding fragment thereof is not available, but the sequence of the antibody molecule or epitope-binding fragment thereof is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody) by PCR amplification using synthetic primers hybridizable to the 3’ and 5’ ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., supra; and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence by, for example, introducing amino acid substitutions, deletions, and/or insertions into the epitope-binding domain regions of the antibodies or any portion of antibodies which may enhance or reduce biological activities of the antibodies.

Recombinant expression of an antibody requires construction of an expression vector containing a nucleotide sequence that encodes the antibody. Once a nucleotide sequence encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art as discussed in the previous sections. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The nucleotide sequence encoding the heavy-chain variable region, light-
chain variable region, both the heavy-chain and light-chain variable regions, an epitope-binding fragment of the heavy- and/or light-chain variable region, or one or more complementarity determining regions (CDRs) of an antibody may be cloned into such a vector for expression. Thus-prepared expression vector can be then introduced into appropriate host cells for the expression of the antibody. Accordingly, the invention includes host cells containing a polynucleotide encoding an antibody specific for the polypeptides of the invention or fragments thereof.

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides or different selectable markers to ensure maintenance of both plasmids. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature, 322:52, 1986; and Kohler, Proc. Natl. Acad. Sci. USA, 77:2 197, 1980). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

In another embodiment, antibodies can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains, such as Fab and Fv or disulfide-bond stabilized Fv, expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage, including fd and M13. The antigen binding domains are expressed as a recombinantly fused protein to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the immunoglobulins, or fragments thereof, of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods, 182:41-50, 1995; Ames et al., J. Immunol. Methods, 184:177-186, 1995; Kettleborough et al., Eur. J. Immunol., 24:952-958, 1994; Persic et al., Gene, 187:9-18, 1997; Burton et al., Advances in Immunology, 57:191-280.
1994; PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired fragments, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(\(ab\)'\(\)2) fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques, 12(6):864-869, 1992; and Sawai et al., AJRI, 34:26-34, 1995; and Better et al., Science, 240:1041-1043, 1988 (each of which is incorporated by reference in its entirety). Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patent Nos. 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology, 203:46-88, 1991; Shu et al., PNAS, 90:7995-7999, 1993; and Skerra et al., Science, 240:1038-1040, 1988.

Once an antibody molecule of the invention has been produced by any methods described above, it may then be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A or Protein G purification, and sizing column chromatography), centrifugation, differential solubility, or by any other standard techniques for the purification of proteins. Further, the antibodies of the present invention or fragments thereof may be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification.

For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a constant region derived from a human immunoglobulin. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science, 229:1202, 1985; Oi et al., BioTechniques, 4:214 1986; Gillies et al., J. Immunol.
Methods, 125:191-202, 1989; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entireties. Humanized antibodies are antibody molecules from non-human species that bind the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature, 332:323, 1988, which are incorporated herein by reference in their entireties. Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101 and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology, 28(4/5):489-498, 1991; Studnicka et al., Protein Engineering, 7(6):805-814, 1994; Roguska et al., Proc Natl. Acad. Sci. USA, 91:969-973, 1994), and chain shuffling (U.S. Patent No. 5,565,332), all of which are hereby incorporated by reference in their entireties.

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645; WO 98/50433; WO 98/24893; WO 98/16654; WO 96/34096; WO 96/33735; and WO 91/10741, each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol., 13:65-93, 1995. For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO
98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entireties. In addition, companies such as Abgenix, Inc. (Fremont, CA), Medarex (NJ) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology, 12:899-903, 1988).

Antibodies fused or conjugated to heterologous polypeptides may be used in in vitro immunoassays and in purification methods (e.g., affinity chromatography) well known in the art. See e.g., PCT publication Number WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett., 39:91-99, 1994; U.S. Patent 5,474,981; Gillies et al., PNAS, 89:1428-1432, 1992; and Fell et al., J. Immunol., 146:2446-2452, 1991, which are incorporated herein by reference in their entireties.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the polypeptides of the invention or fragments, derivatives, analogs, or variants thereof, or similar molecules having the similar enzymatic activities as the polypeptide of the invention. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

5.6 Pharmaceutical Compositions and Kits

The present invention encompasses pharmaceutical compositions comprising antiviral agents of the present invention. In a specific embodiment, the anti-viral agent is an antibody which immunospecifically binds and neutralize the hSARS virus or variants thereof, or any proteins derived therefrom (see Section 5.5). In another specific embodiment, the anti-viral agent is a polypeptide or nucleic acid molecule of the invention (see, for example, Sections 5.1 and 5.2). The pharmaceutical compositions have utility as an anti-viral prophylactic agent and may be administered to a subject where the subject has been exposed or is expected to be exposed to a virus.
Various delivery systems are known and can be used to administer the pharmaceutical composition of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429 4432).

Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In a preferred embodiment, it may be desirable to introduce the pharmaceutical compositions of the invention into the lungs by any suitable route. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, by means of a nasal spray, or by means of an implant, said implant being of a porous, non porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) infected tissues.

In another embodiment, the pharmaceutical composition can be delivered in a vesicle, in particular a liposome (see Langer, 1990, Science 249:1527-1533; Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.).

Macromol. Chem. 23:61 (1983); see also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105). In yet another embodiment, a controlled release system can be placed in proximity of the composition’s target, i.e., the lung, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of an live attenuated, inactivated or killed hSARS virus, or recombinant or chimeric hSARS virus, and a pharmaceutically acceptable carrier. In a specific embodiment, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a vehicle or vehicle with which the pharmaceutical composition is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glyceral, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in “Remington’s Pharmaceutical Sciences” by E.W. Martin. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration.
to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The pharmaceutical compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2 ethylamino ethanol, histidine, procaine, etc.

The amount of the pharmaceutical composition of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient’s circumstances. However, suitable dosage ranges for intravenous administration are generally about 20 500 micrograms of active compound per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose response curves derived from in vitro or animal model test systems.

Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of
the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In a preferred embodiment, the kit contains an anti-viral agent of the invention, e.g., an antibody specific for the polypeptides encoded by a nucleotide sequence of SEQ ID NO:1, 11, 13, or 15, or as shown in Figures 11 (SEQ ID NOS:17-239, 241-736 and 738-1107) and 12 (SEQ ID NOS:1109-1589, 1591-1964 and 1966-2470), or any hSARS epitope, or a polypeptide or protein of the present invention, or a nucleic acid molecule of the invention, alone or in combination with adjuvants, antivirals, antibiotics, analgesics, bronchodilators, or other pharmaceutically acceptable excipients.

The present invention further encompasses kits comprising a container containing a pharmaceutical composition of the present invention and instructions to for use.

5.7 Detection Assays

The present invention provides a method for detecting an antibody, which immunospecifically binds to the hSARS virus, in a biological sample, for example blood, serum, plasma, saliva, urine, etc., from a patient suffering from SARS. In a specific embodiment, the method comprising contacting the sample with the hSARS virus, for example, of deposit no. CCTCC-V200303, or having a genomic nucleic acid sequence of SEQ ID NO:15, directly immobilized on a substrate and detecting the virus-bound antibody directly or indirectly by a labeled heterologous anti-isotype antibody. In another specific embodiment, the sample is contacted with a host cell which is infected by the hSARS virus, for example, of deposit no. CCTCC-V200303, or having a genomic nucleic acid sequence of SEQ ID NO:15, and the bound antibody can be detected by immunofluorescent assay as described in Section 6.5, infra.

An exemplary method for detecting the presence or absence of a polypeptide or nucleic acid of the invention in a biological sample involves obtaining a biological sample from various sources and contacting the sample with a compound or an agent capable of detecting an epitope or nucleic acid (e.g., mRNA, genomic DNA) of the hSARS virus such that the presence of the hSARS virus is detected in the sample. A preferred agent for detecting hSARS mRNA or genomic RNA of the invention is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic RNA encoding a polypeptide of the invention.
The nucleic acid probe can be, for example, a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO:1, 11, 13, or 15, or a portion thereof, such as an oligonucleotide of at least 15, 20, 25, 30, 50, 100, 250, 500, 750, 1,000 or more contiguous nucleotides in length and sufficient to specifically hybridize under stringent conditions to a hSARS mRNA or genomic RNA.

In another preferred specific embodiment, the presence of hSARS virus is detected in the sample by an reverse transcription polymerase chain reaction (RT-PCR) using the primers that are constructed based on a partial nucleotide sequence of the genome of hSARS virus, for example, that of deposit accession no. CCTCC-V200303, or having a genomic nucleic acid sequence of SEQ ID NO:15, or based on a nucleotide sequence of SEQ ID NO:1, 11, 13, or 15. In a non-limiting specific embodiment, preferred primers to be used in a RT-PCR method are: 5’-TACACACCTCAGC-GTTG-3’ (SEQ ID NO:3) and 5’-CACGAACGTGACG-AAT-3’ (SEQ ID NO:4), in the presence of 2.5 mM MgCl₂ and the thermal cycles are, for example, but not limited to, 94 °C for 8 min followed by 40 cycles of 94 °C for 1 min, 50 °C for 1 min, 72 °C for 1 min (also see Section 6.7, infra).

In more preferred specific embodiment, the present invention provides a real-time quantitative PCR assay to detect the presence of hSARS virus in a biological sample by subjecting the cDNA obtained by reverse transcription of the extracted total RNA from the sample to PCR reactions using the specific primers, such as those having nucleotide sequences of SEQ ID NOS:3 and 4, and a fluorescence dye, such as SYBR® Green I, which fluoresces when bound non-specifically to double-stranded DNA. The fluorescence signals from these reactions are captured at the end of extension steps as PCR product is generated over a range of the thermal cycles, thereby allowing the quantitative determination of the viral load in the sample based on an amplification plot (see Section 6.7, infra).

A preferred agent for detecting hSARS is an antibody that specifically binds a polypeptide of the invention or any hSARS epitope, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab’))² can be used.

The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling
include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The detection method of the invention can be used to detect mRNA, protein (or any epitope), or genomic RNA in a sample in vitro as well as in vivo. For example, in vitro techniques for detection of mRNA include northern hybridizations, in situ hybridizations, RT-PCR, and RNase protection. In vitro techniques for detection of an epitope of hSARS include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of genomic RNA include northern hybridizations, RT-PCT, and RNase protection.

Furthermore, in vivo techniques for detection of hSARS include introducing into a subject organism a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in the subject organism can be detected by standard imaging techniques, including autoradiography.

In a specific embodiment, the methods further involve obtaining a control sample from a control subject, contacting the control sample with a compound or agent capable of detecting hSARS, e.g., a polypeptide of the invention or mRNA or genomic RNA encoding a polypeptide of the invention, such that the presence of hSARS or the polypeptide or mRNA or genomic RNA encoding the polypeptide is detected in the sample, and comparing the absence of hSARS or the polypeptide or mRNA or genomic RNA encoding the polypeptide in the control sample with the presence of hSARS, or the polypeptide or mRNA or genomic DNA encoding the polypeptide in the test sample.

The invention also encompasses kits for detecting the presence of hSARS or a polypeptide or nucleic acid of the invention in a test sample. The kit, for example, can comprise a labeled compound or agent capable of detecting hSARS or the polypeptide or a nucleic acid molecule encoding the polypeptide in a test sample and, in certain embodiments, a means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits can also include instructions for use.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide of the invention or hSARS epitope;
and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide of the invention or to a sequence within the hSARS genome or (2) a pair of primers useful for amplifying a nucleic acid molecule containing an hSARS sequence. The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit is usually enclosed within an individual container and all of the various containers are within a single package along with instructions for use.

5.8 Screening Assays to Identify Anti-Viral Agents

The invention provides methods for the identification of a compound that inhibits the ability of hSARS virus to infect a host or a host cell. In certain embodiments, the invention provides methods for the identification of a compound that reduces the ability of hSARS virus to replicate in a host or a host cell. Any technique well-known to the skilled artisan can be used to screen for a compound that would abolish or reduce the ability of hSARS virus to infect a host and/or to replicate in a host or a host cell.

In certain embodiments, the invention provides methods for the identification of a compound that inhibits the ability of hSARS virus to replicate in a mammal or a mammalian cell. More specifically, the invention provides methods for the identification of a compound that inhibits the ability of hSARS virus to infect a mammal or a mammalian cell. In certain embodiments, the invention provides methods for the identification of a compound that inhibits the ability of hSARS virus to replicate in a mammalian cell. In a specific embodiment, the mammalian cell is a human cell.

In another embodiment, a cell is contacted with a test compound and infected with the hSARS virus. In certain embodiments, a control culture is infected with the hSARS virus in the absence of a test compound. The cell can be contacted with a test compound before, concurrently with, or subsequent to the infection with the hSARS virus. In a specific embodiment, the cell is a mammalian cell. In an even more specific embodiment,
the cell is a human cell. In certain embodiments, the cell is incubated with the test compound for at least 1 minute, at least 5 minutes at least 15 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 5 hours, at least 12 hours, or at least 1 day. The titer of the virus can be measured at any time during the assay. In certain embodiments, a time course of viral growth in the culture is determined. If the viral growth is inhibited or reduced in the presence of the test compound, the test compound is identified as being effective in inhibiting or reducing the growth or infection of the hSARS virus. In a specific embodiment, the compound that inhibits or reduces the growth of the hSARS virus is tested for its ability to inhibit or reduce the growth rate of other viruses to test its specificity for the hSARS virus.

In one embodiment, a test compound is administered to a model animal and the model animal is infected with the hSARS virus. In certain embodiments, a control model animal is infected with the hSARS virus without the administration of a test compound. The test compound can be administered before, concurrently with, or subsequent to the infection with the hSARS virus. In a specific embodiment, the model animal is a mammal. In an even more specific embodiment, the model animal can be, but is not limited to, a cotton rat, a mouse, or a monkey. The titer of the virus in the model animal can be measured at any time during the assay. In certain embodiments, a time course of viral growth in the culture is determined. If the viral growth is inhibited or reduced in the presence of the test compound, the test compound is identified as being effective in inhibiting or reducing the growth or infection of the hSARS virus. In a specific embodiment, the compound that inhibits or reduces the growth of the hSARS in the model animal is tested for its ability to inhibit or reduce the growth rate of other viruses to test its specificity for the hSARS virus.

6. EXAMPLES

The following examples illustrate the isolation and identification of the novel hSARS virus. These examples should not be construed as limiting.

METHODS AND RESULTS

6.1 Clinical Subjects

The study included all 50 patients who fitted a modified World Health Organization (WHO) definition of SARS and were admitted to 2 acute regional hospitals in Hong Kong Special Administrative Region (HKSAR) between February 26 to March 26, 2003 (WHO. Severe acute respiratory syndrome (SARS) Weekly Epidemiol Rec. 2003; 78: 81-83). A lung biopsy from an additional patient, who had typical SARS and was admitted to a third hospital, was also included in the study. Briefly, the case definition for SARS was: (i) fever of 38°C or more; (ii) cough or shortness of breath; (iii) new pulmonary infiltrates on chest radiograph; and (iv) either a history of exposure to a patient with SARS or absence of response to empirical antimicrobial coverage for typical and atypical pneumonia (beta-lactams and macrolides, fluoroquinolones or tetracyclines).

Nasopharyngeal aspirates and serum samples were collected from all patients. Paired acute and convalescent sera and feces were available from some patients. Lung biopsy tissue from one patient was processed for a viral culture, RT-PCR, routine histopathological examination, and electron microscopy. Nasopharyngeal aspirates, feces and sera submitted for microbiological investigation of other diseases were included in the study under blinding and served as controls.

The medical records were reviewed retrospectively by the attending physicians and clinical microbiologists. Routine hematological, biochemical and microbiological examinations, including bacterial culture of blood and sputum, serological study and collection of nasopharyngeal aspirates for virological tests, were carried out.

6.2 Cell Line

FRhK-4 (fetal rhesus monkey kidney) cells were maintained in minimal essential medium (MEM) with 1% fetal calf serum, 1% streptomycin and penicillin, 0.2% nystatin and 0.05% garamycin.

6.3 Viral Infection
Two-hundred µl of clinical (nasopharyngeal aspirates) samples, from two patients (see the Result section, infra), in virus transport medium were used to infect FRhK-4 cells. The inoculated cells were incubated at 37°C for 1 hour. One ml of MEM containing 1 µg trypsin was then added to the culture and the infected cells were incubated in a 37°C incubator supplied with 5% carbon dioxide. Cytopathic effects were observed in the infected cells after 2 to 4 days of incubation. The infected cells were passaged into new FRhK-4 cells and cytopathic effects were observed within 1 day after the inoculation. The infected cells were tested by an immunofluorescent assay for influenza A, influenza B, respiratory syncytial virus, parainfluenza types 1, 2 and 3, adenovirus and human metapneumovirus (hMPV) and negative results were obtained for all cases. The infected cells were also tested by RT-PCR for influenza A and human metapneumovirus with negative results.

6.4 Virus Morphology

The infected cells prepared as described above were harvested, pelleted by centrifugation and the cell pellets were processed for thin-section transmitted electron microscopic visualization. Viral particles were identified in the cells infected with both clinical specimens, but not in control cells which were not infected with the virus. Virions isolated from the infected cells were about 70-100 nanometers (Figure 2). Viral capsids were found predominantly within the vesicles of the golgi and endoplasmic reticulum and were not free in the cytoplasm. Virus particles were also found at the cell membrane.

One virus isolate was ultracentrifuged and the cell pellet was negatively stained using phosphotungstic acid. Virus particles characteristic of Coronaviridae were thus visualized. Since the human Coronaviruses hitherto recognized are not known to cause a similar disease, the present inventors postulated that the virus isolates represent a novel virus that infects humans.

6.5 Antibody Response to the Isolated Virus

To further confirm that this novel virus is responsible for causing SARS in the infected patients, blood serum samples from the patients who were suffering from SARS were obtained and a neutralization test was performed. Typically diluted serum (x50, x200, x800 and x1600) was incubated with acetone-fixed FRhK-4 cells infected with hSARS at
37°C for 45 minutes. The incubated cells were then washed with phosphate-buffered saline and stained with anti-human IgG-FITC conjugated antibody. The cells were then washed and examined under a fluorescent microscope. In these experiments, positive signals were found in 8 patients who had SARS (Figure 3), indicating that these patients had an IgG antibody response to this novel human respiratory virus of *Coronaviridae*. By contrast, no signal was detected in 4 negative-control paired sera. The serum titers of anti-hSARS antibodies of the tested patients are shown in Table 1.

### Table 1

<table>
<thead>
<tr>
<th>Name</th>
<th>Date</th>
<th>Lab No.</th>
<th>Anti-SARS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient A</td>
<td>25-Feb-03</td>
<td>S2728</td>
<td>&lt;50</td>
</tr>
<tr>
<td></td>
<td>6-Mar-03</td>
<td>S2728</td>
<td>1600</td>
</tr>
<tr>
<td>Patient B</td>
<td>25-Feb-03</td>
<td>S2441</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>3-Mar-03</td>
<td>S2441</td>
<td>200</td>
</tr>
<tr>
<td>Patient C</td>
<td>4-Mar-03</td>
<td>S3279</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>14-Mar-03</td>
<td>S3279</td>
<td>1600</td>
</tr>
<tr>
<td>Patient D</td>
<td>6-Mar-03</td>
<td>M41045</td>
<td>&lt;50</td>
</tr>
<tr>
<td></td>
<td>11-Mar-03</td>
<td>MB943703</td>
<td>800</td>
</tr>
<tr>
<td>Patient E</td>
<td>4-Mar-03</td>
<td>M38953</td>
<td>&lt;50</td>
</tr>
<tr>
<td></td>
<td>18-Mar-03</td>
<td>KWH03/3601</td>
<td>800</td>
</tr>
<tr>
<td>Control F</td>
<td>13-Feb-03</td>
<td>M27124</td>
<td>&lt;50</td>
</tr>
<tr>
<td></td>
<td>1-Mar-03</td>
<td>MB942968</td>
<td>&lt;50</td>
</tr>
<tr>
<td>Patient G</td>
<td>3-Mar-03</td>
<td>M38685</td>
<td>&lt;50</td>
</tr>
<tr>
<td></td>
<td>7-Mar-03</td>
<td>KWH03/2900</td>
<td>Equivocal</td>
</tr>
</tbody>
</table>

**Blinded samples:**

1a * Acute <50  
1b Convalescent 1600  
2a * Acute 50  
2b Convalescent >1600  
3a * Acute 50  
3b Convalescent >1600  
4a * Acute <50  
4b Convalescent <50  
5a * Acute <50  
5b Convalescent <50  
6a * Acute <50  
6b Convalescent <50

**NB:** *patients with SARS*
These results indicated that this novel member of *Coronaviridae* is a key pathogen in SARS.

### 6.6 Sequences of the hSARS Virus

Total RNA from infected or uninfected FRHK-4 cells was harvested two days post-infection. One-hundred ng of purified RNA was reverse transcribed using Superscript\textsuperscript{®} II reverse transcriptase (Invitrogen) in a 20 µl reaction mixture containing 10 pg of a degenerated primer (5'-GCCGGAGCTCTGCAGAATTCSNNN-3': SEQ ID NO:5; N=A, T, G or C) as recommended by the manufacturer. Reverse transcribed products were then purified by a QIAquick\textsuperscript{®} PCR purification kit as instructed by the manufacturer and eluted in 30 µl of 10 mM Tris-HCl, pH 8.0. Three µl of purified cDNA products were added in a 25 µl reaction mixture containing 2.5 µl of 10x PCR buffer, 4 µl of 25 mM MgCl\textsubscript{2}, 0.5 µl of 10 mM dNTP, 0.25 µl of AmpliTaq Gold\textsuperscript{®} DNA polymerase (Applied Biosystems), 2.5 µCi of [\textsuperscript{32}P]CTP (Amersham), 2 µl of 10 µM primer (5'-GCCGGAGCTCTGCAGAATT-C-3': SEQ ID NO:6). Reactions were thermal cycled through the following profile: 94°C for 8 min followed by 2 cycles of 94°C for 1 min, 40°C for 1 min, 72°C for 2 min. This temperature profile was followed by 35 cycles of 94°C for 1 min, 60°C for 1 min, 72°C for 1 min. 6 µl of the PCR products were analyzed in a 5% denaturing polyacrylamide gel electrophoresis. Gel was exposed to X-ray film and the film was developed after an over-night exposure. Unique PCR products which were only identified in infected cell samples were isolated from the gel and eluted in a 50 µl of 1x TE buffer. Eluted PCR products were then re-amplified in 25 µl of reaction mixture containing 2.5 µl of 10x PCR buffer, 4 µl of 25 mM MgCl\textsubscript{2}, 0.5 µl of 10 mM dNTP, 0.25 µl of AmpliTaq Gold\textsuperscript{®} DNA polymerase (Applied Biosystems), 1 µl of 10 µM primer (5'-GCCGGAGCTCTGCAGAATT-C-3':SEQ ID NO:6). Reaction mixtures were thermal cycled through the following profile: 94°C for 8 min followed by 35 cycles of 94°C for 1 min, 60°C for 1 min, 72°C for 1 min. PCR products were cloned using a TOPO TA Cloning\textsuperscript{®} kit (Invitrogen) and ligated plasmids were transformed into TOP10 *E. coli* competent cells (Invitrogen). PCR inserts were sequenced by a BigDye cycle sequencing kit as recommended by the manufacturer (Applied Biosystems) and sequencing products were analyzed by an automatic sequencer (Applied Biosystems, model number 3770). The obtained sequence (SEQ ID NO:1) is shown in Figure 1. The deduced amino acid
sequence (SEQ ID NO:2) from the obtained DNA sequence showed 57% homology to the polymerase protein of identified coronaviruses.

Similarly, two other partial sequences (SEQ ID NOS:11 and 13) and deduced amino acid sequences (SEQ ID NOS:12 and 14, respectively) were obtained from the hSARS virus and are shown in Figures 8 (SEQ ID NOS:11 and 12) and 9 (SEQ ID NOS:13 and 14).

The entire genomic sequence of hSARS virus is shown in Figure 10 (SEQ ID NO:15). The deduced amino acid sequences of SEQ ID NO:15 in all three frames are shown in Figure 11 (nucleotide sequences shown in SEQ ID NOS:16, 240 and 737; for amino acid sequences, see SEQ ID NO:17-239, 241-736 and 738-1107). The deduced amino acid sequences of the complement of SEQ ID NO:15 in all three frames are shown in Figure 12 (nucleotide sequences shown in SEQ NOS:1108, 1590 and 1965; for amino acid sequences, see SEQ ID NOS:1109-1589, 1591-1964 and 1966-2470).

6.7 Detection of hSARS Virus in Nasopharyngeal Aspirates

First, the nasopharyngeal aspirates (NPA) were examined by rapid immunofluorescent antigen detection for influenza A and B, parainfluenza types 1, 2 and 3, respiratory syncytial virus and adenovirus (Chan KH, Maldeis N, Pope W, Yup A, Ozinskas A, Gill J, Seto WH, Shortridge KF, Peiris JSM. Evaluation of Directigen Fly A+B test for rapid diagnosis of influenza A and B virus infections. J Clin Microbiol. 2002; 40: 1675-1680) and were cultured for conventional respiratory pathogens on Mardin Darby Canine Kidney, LLC-Mk2, RDE, Hep-2 and MRC-5 cells (Wiedbrauk DL, Johnston SLG. Manual of clinical virology. Raven Press, New York. 1993). Subsequently, fetal rhesus kidney (FRhk-4) and A-549 cells were added to the panel of cell lines used. Reverse transcription polymerase chain reaction (RT-PCR) was performed directly on the clinical specimen for influenza A (Fouchier RA, Bestebroer TM, Herfst S, Van Der Kemp L, Rimmelzwaan GF, Osterhaus AD. Detection of influenza A virus from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol. 2000; 38: 4096-101) and human metapneumovirus (HMPV). The primers used for HMPV were: for first round, 5’-AARGTSAATGCATCACG-3’ (SEQ ID NO. 7) and 5’-CATAATTGTCTCTGCTTTC-3’ (SEQ ID NO:8); and nested primers: 5’-ACACCTGTTAATACCCAGC-3’ (SEQ ID NO:9) and 5’-GACTTGAGTCCAGCTCCA-3’ (SEQ ID NO:10). The size of the nested
PCR product was 201 bp. An ELISA for mycoplasma was used to screen cell cultures (Roche Diagnostics GmbH, Roche, Indianapolis, USA).

**RT-PCR Assay**

Subsequent to culturing and genetic sequencing of the hSARS virus from two patients (*see Section 6.6, supra*), an RT-PCR was developed to detect the hSARS virus sequence from NPA samples. Total RNA from clinical samples was reverse transcribed using random hexamers and cDNA was amplified using primers 5’-TACACACCTCAGC-GTTG-3’ (SEQ ID NO:3) and 5’-CACGAACGTGACGAAAT-3’ (SEQ ID NO:4), which are constructed based on the RNA-dependent RNA polymerase-encoding sequence (SEQ ID NO:1) of the hSARS virus in the presence of 2.5 mM MgCl₂ (94 °C for 8 min followed by 40 cycles of 94 °C for 1 min, 50 °C for 1 min, 72 °C for 1 min).

The summary of a typical RT-PCR protocol is as follows:

1. **RNA extraction**
   
   RNA from 140 μl of NPA samples is extracted by QIAquick viral RNA extraction kit and is eluted in 50 μl of elution buffer.

2. **Reverse transcription**
   
<table>
<thead>
<tr>
<th>Complement</th>
<th>Volume (μl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA</td>
<td>11.5 μl</td>
</tr>
<tr>
<td>0.1 M DTT</td>
<td>2 μl</td>
</tr>
<tr>
<td>5x buffer</td>
<td>4 μl</td>
</tr>
<tr>
<td>10 mM dNTP</td>
<td>1 μl</td>
</tr>
<tr>
<td>Superscript II, 200 U/μl (Invitrogen)</td>
<td>1 μl</td>
</tr>
<tr>
<td>Random hexamers, 0.3 μg/μl</td>
<td>0.5 μl</td>
</tr>
</tbody>
</table>

   Reaction condition: 42 °C, 50 min
   94 °C, 3 min
   4 °C

3. **PCR**
   
   cDNA generated by random primers is amplified in a 50 μl reaction as follows:
cDNA  2 µl
10 mM dNTP  0.5 µl
10x buffer  5 µl
25 mM MgCl₂  5 µl
25 µM Forward primer  0.5 µl
25 µM Reverse primer  0.5 µl
AmpliTaq Gold® polymerase, 5U/µl (Applied Biosystems)  0.25 µl
Water  36.25 µl

Thermal-cycle condition: 95°C, 10 min, followed by 40 cycles of 95 °C, 1 min; 50°C 1 min; 72 °C, 1 min.

4. Primer sequences

Primers were designed based on the RNA-dependent RNA polymerase encoding sequence (SEQ ID NO:1) of the hSARS virus.

Forward primer: 5’ TACACACCTCAGCGTGTG 3’ (SEQ ID NO:3)
Reverse primer: 5’ CACGAACGTCGAGAAT 3’ (SEQ ID NO:4)

Product size: 182 bps

**Real-Time Quantitative PCR Assay**

Total RNA from 140 µl of nasopharyngeal aspirate (NPA) was extracted by QIAamp® virus RNA mini kit (Qiagen) as instructed by the manufacturer. Ten µl of eluted RNA samples were reverse transcribed by 200 U of Superscript® II reverse transcriptase (Invitrogen) in a 20 µl reaction mixture containing 0.15 µg of random hexamers, 10 mmol/L DTT, and 0.5 mmol/L dNTP, as instructed. Complementary DNA was then amplified in a SYBR® Green I fluorescence reaction (Roche) mixtures. Briefly, 20 µl reaction mixtures containing 2 µl of cDNA, 3.5 mmol/L MgCl₂, 0.25 µmol/L of forward primer (5’-TACACACCTCAGCGTGTG-3’; SEQ ID NO:3) and 0.25 µmol/L reverse primer (5’-CACGAACGTCGAGAAT-3’; SEQ ID NO:4) were thermal-cycled by a Light-Cycler (Roche) with the PCR program, [ 95°C, 10 min followed by 50 cycles of 95°C, 10 min;
57°C, 5 sec; 72°C 9 sec]. Plasmids containing the target sequence were used as positive controls. Fluorescence signals from these reactions were captured at the end of extension step in each cycle (see Fig. 7A). To determine the specificity of the assay, PCR products (184 base pairs) were subjected to a melting curve analysis at the end of the assay (65°C to 95°C, 0.1 °C per second; see Fig. 7B).

**CLINICAL RESULTS**

Clinical findings:

All 50 patients with SARS were ethnic Chinese. They represented 5 different epidemiologically linked clusters as well as additional sporadic cases fitting the case definition. They were hospitalized at a mean of 5 days after the onset of symptoms. The median age was 42 years (range of 23 to 74) and the female to male ratio was 1.3. Fourteen (28%) were health care workers and five (10%) had a history of visit to a hospital experiencing a major outbreak of SARS. Thirteen (26%) patients had household contacts and 12 (24%) others had social contacts with patients with SARS. Four (8%) had a history of recent travel to mainland China.

The major complaints from most patients were fever (90%) and shortness of breath. Cough and myalgia were present in more than half the patients (Table 2). Upper respiratory tract symptoms such as rhinorrhea (24%) and sore throat (20%) were present in a minority of patients. Diarrhea (10%) and anorexia (10%) were also reported. At initial examination, auscultatory findings, such as crepitations and decreased air entry, were present in only 38% of patients. Dry cough was reported by 62% of patients. All patients had radiological evidence of consolidation, at the time of admission, involving 1 zone (in 36), 2 zones (13) and 3 zones (1).

<table>
<thead>
<tr>
<th>Clinical symptoms</th>
<th>Number (percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>50 (100%)</td>
</tr>
<tr>
<td>Chill or rigors</td>
<td>37 (74%)</td>
</tr>
<tr>
<td>Cough</td>
<td>31 (62%)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>27 (54%)</td>
</tr>
<tr>
<td>Malaise</td>
<td>25 (50%)</td>
</tr>
<tr>
<td>Running nose</td>
<td>12 (24%)</td>
</tr>
<tr>
<td>Sore throat</td>
<td>10 (20%)</td>
</tr>
</tbody>
</table>
In spite of the high fever, most patients (98%) had no evidence of a leukocytosis. Lymphopenia (68%), leucopenia (26%), thrombocytopenia (40%) and anemia (18%) were present in peripheral blood examination (Table 3). Parenchymal liver enzyme, alanine aminotransferase (ALT) and muscle enzyme, creatinine kinase (CPK) were elevated in 34% and 26% respectively.

Table 3

<table>
<thead>
<tr>
<th>Laboratory parameter</th>
<th>Mean (range)</th>
<th>Percentage of abnormal</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemoglobin</td>
<td>12.9 (8.9 - 15.9)</td>
<td></td>
<td>11.5 - 16.5 g/dl</td>
</tr>
<tr>
<td>Anaemia</td>
<td>9 (18%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White cell count</td>
<td>5.17 (1.1 - 11.4)</td>
<td></td>
<td>4 - 11 x 10⁹ /L</td>
</tr>
<tr>
<td>Leucopenia</td>
<td>13 (26%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocyte count</td>
<td>0.78 (0.3 - 1.5)</td>
<td></td>
<td>1.5 - 4.0 x 10⁹ /L</td>
</tr>
<tr>
<td>Significant lymphopenia</td>
<td>34 (68%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(&lt;1.0 x 10⁹ /L)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platelet count</td>
<td>174 (88 - 351)</td>
<td></td>
<td>150 - 400 x 10⁹ /L</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>20 (40%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alanine aminotransaminase (ALT)</td>
<td>63 (11 - 350)</td>
<td></td>
<td>6 - 53 U/L</td>
</tr>
<tr>
<td>Elevated ALT</td>
<td>17 (34%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>37 (26 - 50)</td>
<td></td>
<td>42 - 54 g/L</td>
</tr>
<tr>
<td>Low albumin</td>
<td>34 (68%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Globulin</td>
<td>33 (21 - 42)</td>
<td></td>
<td>24 - 36 g/L</td>
</tr>
<tr>
<td>Elevated globulin</td>
<td>10 (20%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine kinase</td>
<td>244 (31 - 1379)</td>
<td></td>
<td>34 - 138 U/L</td>
</tr>
</tbody>
</table>
Elevated creatinine kinase 13 (26%)

Routine microbiological investigations for known viruses and bacteria by culture, antigen detection, and PCR were negative in most cases. Blood culture was positive for *Escherichia coli* in a 74-year-old male patient, who was admitted to intensive care unit, and was attributed to hospital acquired urinary tract infection. *Klebsiella pneumoniae* and *Hemophilus influenzae* were isolated from the sputum specimens of 2 other patients on admission.

Oral levofloxacin 500 mg q24h was given in 9 patients and intravenous (1.2 g q8h)/oral (375 mg tid) amoxicillin-clavulanate and intravenous/oral clarithromycin 500 mg q12h were given in another 40 patients. Four patients were given oral oseltamivir 75 mg bid. In one patient, intravenous ceftriaxone 2 gm q24h, oral azithromycin 500 mg q24h, and oral amantadine 100 mg bid were given for empirical coverage of typical and atypical pneumonia.

Nineteen patients progressed to severe disease with oxygen desaturation and were required intensive care and ventilatory support. The mean number of days of deterioration from the onset of symptoms was 8.3 days. Intravenous ribavirin 8 mg/kg q8h and steroid was given in 49 patients at a mean day of 6.7 after onset of symptoms.

The risk factors associated with severe complicated disease requiring intensive care and ventilatory support were older age, lymphopenia, impaired ALT, and delayed initiation of ribavirin and steroid (Table 4). All the complicated cases were treated with ribavirin and steroid after admission to the intensive care unit whereas all the uncomplicated cases were started on ribavirin and steroid in the general ward. As expected, 31 uncomplicated cases recovered or improved whereas 8 complicated cases deteriorated with one death at the time of writing. All 50 patients were monitored for a mean of 12 days at the time of writing.
| Table 4 |
|-----------------|-----------------|------------------|
|                | Complicated case (n= 19) | Uncomplicated case (n= 31) | P value |
| Mean (SD) age (range) | 49.5 ± 12.7 | 39.0 ± 10.7 | P < 0.01 |
| Male / Female ratio | 8 / 11 | 14 / 17 | N.S. |
| Underlying illness | 5 † | 1 ‡ | P < 0.05 |
| Mode of contact | | | |
| Travel to China | 1 | 3 | N.S. |
| Health care worker | 5 | 9 | N.S. |
| Hospital visit | 1 | 4 | N.S. |
| Household contact | 8 | 5 | P < 0.05 |
| Social contact | 4 | 10 | N.S. |
| Mean (SD) duration of symptoms to admission (days) | 5.2 ± 2.0 | 4.7 ± 2.5 | N.S. |
| Mean (SD) admission temperature (°C) | 38.8 ± 0.9 | 38.7 ± 0.8 | N.S. |
| Mean (SD) initial total peripheral WBC count (x 10^9 / L) | 5.1 ± 2.4 | 5.2 ± 1.8 | N.S. |
| Mean (SD) initial lymphocyte count (x 10^9 / L) | 0.66 ± 0.3 | 0.85 ± 0.3 | P < 0.05 |
| Presence of thrombocytopenia (< 150 x 10^9 / L) | 8 | 12 | N.S. |
| Impaired liver function test | 11 | 6 | P < 0.01 |
| CXR changes (number of zone affected) | 1.4 | 1.2 | N.S. |
| Mean (SD) day of deterioration from the onset of symptoms § | 8.3 ± 2.6 | Not applicable |
| Mean (SD) day of initiation of Ribavirin & steroid from the onset of symptoms | 7.7 ± 2.9 | 5.7 ± 2.6 | P < 0.05 |
| Initiation of ribavirin & steroid after deterioration | 12 | 0 | P < 0.001 |
| Response to ribavirin & steroid | | | |
| Outcome | | | |
| Improved or recovered | 10 | 31 | P < 0.01 |
| Not improving || 8 | 0 | P < 0.01 |

* Multi-variant analysis is not performed due to low number of cases;† 2 patients had diabetic mellitus, 1 had hypertrophic obstructive cardiomyopathy, 1 had chronic active hepatitis B, and 1 had brain tumour;‡ 1 patient had essential hypertension;§ desaturation requiring intensive care support; || 1 died.
Two virus isolates, subsequently identified as a member of *Coronaviridae* (see below), were isolated from two patients. One was from an open lung biopsy tissue of a 53-year-old Hong Kong Chinese resident and the other from a nasopharyngeal aspirate of a 42-year-old female with good previous health. The 53-year-old male had a history of 10-hour household contact with a Chinese visitor who came from Guangzhou and later died from SARS. Two days after this exposure, he presented with fever, malaise, myalgia, and headache. Crepitations were present over the right lower zone and there was a corresponding alveolar shadow on the chest radiograph. Hematological investigation revealed lymphopenia of $0.7 \times 10^9/L$ with normal total white cell and platelet counts. Both ALT (41 U/L) and CPK (405 U/L) were impaired. Despite a combination of oral azithromycin, amantadine, and intravenous ceftriaxone, there was increasing bilateral pulmonary infiltrates and progressive oxygen desaturation. Therefore, an open lung biopsy was performed 9 days after admission. Histopathological examination showed a mild interstitial inflammation with scattered alveolar pneumocytes showing cytomegaly, granular amphiphilic cytoplasm and enlarged nuclei with prominent nucleoli. No cells showed inclusions typical of herpesvirus or adenovirus infection. The patient required ventilation and intensive care after the operative procedure. Empirical intravenous ribavirin and hydrocortisone were given. He succumbed 20 days after admission. In retrospect, coronavirus-like RNA was detected in his nasopharyngeal aspirate, lung biopsy and post-mortem lung. He had a significant rise in titer of antibodies against his own hSARS isolate from 1/200 to 1/1600.

The second patient from whom a hSARS virus was isolated, was a 42-year-old female with good past health. She had a history of travel to Guangzhou in mainland China for 2 days. She presented with fever and diarrhea 5 days after her return to Hong Kong. Physical examination showed crepitation over the right lower zone which had a corresponding alveolar shadow on the chest radiograph. Investigation revealed leucopenia ($2.7 \times 10^9/L$), lymphopenia ($0.6 \times 10^9/L$), and thrombocytopenia ($104 \times 10^9/L$). Despite the empirical antimicrobial coverage with amoxicillin-clavulanate, clarithromycin, and oseltamivir, she deteriorated 5 days after admission and required mechanical ventilation and intensive care for 5 days. She gradually improved without receiving treatment with ribavirin or steroid. Her nasopharyngeal aspirate was positive for the virus in the RT-PCR and she was seroconverted from antibody titre $<1/50$ to $1/1600$ against the hSARS isolate.
**Virological findings:**

Viruses were isolated on FRhk-4 cells from the lung biopsy and nasopharyngeal aspirate respectively, of two patients described above. The initial cytopathic effect appeared between 2 and 4 days after inoculation, but on subsequent passage, cytopathic effect appeared in 24 hours. Both virus isolates did not react with the routine panel of reagents used to identify virus isolates including those for influenza A, B parainfluenza types 1, 2, 3, adenovirus and respiratory syncytial virus (DAKO, Glostrup, Denmark). They also failed to react in RT-PCR assays for influenza A and HMPV or in PCR assays for mycoplasma. The virus was ether sensitive, indicating that it was an enveloped virus. Electron microscopy of negatively stained (2% potassium phospho-tungstate, pH 7.0) cell culture extracts obtained by ultracentrifugation showed the presence of pleomorphic enveloped viral particles, of about 80-90 nm (ranging 70-130 nm) in diameter, whose surface morphology appeared comparable to members of *Coronaviridae* (Figure 5A). Thin section electron microscopy of infected cells revealed virus particles of 55-90 nm diameter within the smooth-walled vesicles in the cytoplasm (Figure 5A and 5B). Virus particles were also seen at the cell surface. The overall findings were compatible with infections in the cells caused by viruses of *Coronaviridae*.

A thin section electron micrograph of the lung biopsy of the 53 year old male contained 60-90-nm viral particles in the cytoplasm of desquamated cells. These viral particles were similar in size and morphology to those observed in the cell-cultured virus isolate from both patients (Figure 4).

The RT-PCR products generated in a random primer RT-PCR assay were analyzed and unique bands found in the virus infected specimen was cloned and sequenced. Of 30 clones examined, a clone containing 646 base pairs (SEQ ID NO:1) of unknown origin was identified. Sequence analysis of this DNA fragment suggested this sequence had a weak homology to viruses of the family of *Coronaviridae* (data not shown). Deduced amino acid sequence (215 amino acids: SEQ ID NO:2) from this unknown sequence, however, had the highest homology (57%) to the RNA polymerase of bovine coronavirus and murine hepatitis virus, confirming that this virus belongs to the family of *Coronaviridae*. Phylogenetic analysis of the protein sequences showed that this virus, though most closely related to the group II coronaviruses, was a distinct virus (Figures 5A and 5B).
Based on the 646 bp sequence of the isolate, specific primers for detecting the new virus was designed for RT-PCR detection of this hSARS virus genome in clinical specimens. Of the 44 nasopharyngeal specimens available from the 50 SARS patients, 22 had evidence of hSARS RNA. Viral RNA was detectable in 10 of 18 fecal samples tested. The specificity of the RT-PCR reaction was confirmed by sequencing selected positive RT-PCR amplified products. None of 40 nasopharyngeal and fecal specimens from patients with unrelated diseases were reactive in the RT-PCR assay.

To determine the dynamic range of real-time quantitative PCR, serial dilutions of plasmid DNA containing the target sequence were made and subjected to the real-time quantitative PCR assay. As shown in Figure 7A, the assay was able to detect as little as 10 copies of the target sequence. By contrast, no signal was observed in the water control (Figure 7A). Positive signals were observed in 23 out of 29 serologically confirmed SARS patients. In all of these positive cases, a unique PCR product (T_m = 82°C) corresponding to the signal from the positive control was observed (Figure 7B, and data not shown). These results indicated this assay is highly specific to the target. The copy numbers of the target sequence in these reactions range from 4539 to less than 10. Thus, as high as 6.48 x 10^3 copies of this viral sequence could be found in 1 ml of NPA sample. In 5 of the above positive cases, it was possible to collect NPA samples before seroconversion. Viral RNA was detected in 3 of these samples, indicating that this assay can detect the virus even at the early onset of infection.

To further validate the specificity of this assay, NPA samples from healthy individuals (n=11) and patients suffered from adenovirus (n=11), respiratory syncytial virus (n=11), human metapneumovirus (n=11), influenza A virus (n=13) or influenza B virus (n=1) infection were recruited as negative controls. All of these samples, except one, were negative in the assay. The false positive case was negative in a subsequence test. Taken together, including the initial false positive case, the real-time quantitative PCR assay has sensitivity of 79% and specificity of 98%.

Epidemiological data suggest that droplet transmission is one of the major route of transmission of this virus. The detection of live virus and the detection of high copies of viral sequence from NPA samples in the current study clearly support that cough and sneeze droplets from SARS patients might be the major source of this infectious agent. Interestingly, 2 out of 4 available stool samples form the SARA patients in this study were
positive in the assay (data not shown). The detection of the virus in feces suggests that there might be other routes of transmission. It is relevant to note that a number of animal coronaviruses are spread via the fecal-oral route (McIntosh K., 1974, Coronaviruses: a comparative review. Current Top Microbiol Immunol. 63: 85-112). However, further studies are required to test whether the virus in feces is infectious or not.

Currently, apart from this hSARS virus, there are two known serogroups of human coronaviruses (229E and OC43) (Hruskova J. et al., 1990, Antibodies to human coronaviruses 229E and OC43 in the population of C.R., Acta Virol. 34:346-52). The primer set used in the present assay does not have homology to the strain 229E. Due to the lack of available corresponding OC43 sequence in the Genebank, it is not known whether these primers would cross-react with this strain. However, sequence analyses of available sequences in other regions of OC43 polymerase gene indicate that the novel human virus associated with SARS is genetically distinct from OC43. Furthermore, the primers used in this study do not have homology to any of sequences from known coronaviruses. Thus, it is very unlikely that these primers would cross-react with the strain OC43.

Apart from the novel pathogen, metapneumovirus was reported to be identified in some of SARS patients (Center for Disease Control and Prevention, 2003, Morbidity and Mortality Weekly Report 52: 269-272). No evidence of metapneumovirus infection was detected in any of the patients in this study (data not shown), suggesting that the novel hSARS virus of the invention is the key player in the pathogenesis of SARS.

**Immunofluorescent antibody detection:**

Thirty-five of the 50 most recent serum samples from patients with SARS had evidence of antibodies to the hSARS (see Fig. 3). Of 27 patients from whom paired acute and convalescent sera were available, all were seroconverted or had >4 fold increase in antibody titer to the virus. Five other pairs of sera from additional SARS patients from clusters outside this study group were also tested to provide a wider sampling of SARS patients in the community and all of them were seroconverted. None of 80 sera from patients with respiratory or other diseases as well as none of 200 normal blood donors had detectable antibody.

When either seropositivity to HP-CV in a single serum or viral RNA detection in the NPA or stool are considered evidence of infection with the hSARS, 45 of the 50 patients
had evidence of infection. Of the 5 patients without any virological evidence of 
Coronaviridae viral infection, only one of these patients had their sera tested > 14 days after 
onset of clinical disease.

DISCUSSION

The outbreak of SARS is unusual in a number of aspects, in particular, in the 
appearance of clusters of patients with pneumonia in health care workers and family 
contacts. In this series of patients with SARS, investigations for conventional pathogens of  
atypical pneumonia proved negative. However, a virus that belongs to the family 
Coronaviridae was isolated from the lung biopsy and nasopharyngeal aspirate obtained  
from two SARS patients, respectively. Phylogenetically, the virus was not closely related to  
any known human or animal coronavirus or torovirus. The present analysis is based on a  
646 bp fragment (SEQ ID NO:1) of the polymerase gene and the entire genome of the  
isolated hSARS virus, which indicates that the virus relates to antigenic group 2 of the  
coronaviruses along with murine hepatitis virus and bovine coronavirus. However, viruses 
of the Coronaviridae can undergo heterologous recombination within the virus family and  
genetic analysis of other parts of the genome needs to be carried out before the nature of this  
new virus is more conclusively defined (Holmes KV. Coronaviruses. Eds Knipe DM,  
Howley PM Fields Virology, 4th Edition, Lippincott Williams & Wilkins, Philadelphia,  
1187-1203). The biological, genetic and clinical data, taken together, indicate that the new  
virus is not one of the two known human coronaviruses.

The majority (90%) of patients with clinically defined SARS had either serological  
or RT-PCR evidence of infection by this virus. In contrast, neither antibody nor viral RNA  
was detectable in healthy controls. All 27 patients from whom acute and convalescent sera  
were available demonstrated rising antibody titers to hSARS virus, strengthening the  
contention that a recent infection with this virus is a necessary factor in the evolution of  
SARS. In addition, all five pairs of acute and convalescent sera tested from patients from  
other hospitals in Hong Kong also showed seroconversion to the virus. The five patients  
who has not shown serological or virological evidence of hSARS virus infection, need to  
have later convalescent sera tested to define if they are also seroconverted. However, the  
concordance of the hSARS virus with the clinical definition of SARS appears remarkable,  
given that clinical case definitions are never perfect.
No evidence of HMPV infection, either by RT-PCR or rising antibody titer against HMPV, was detected in any of these patients. No other pathogen was consistently detected in our group of patients with SARS. It is therefore highly likely that that this hSARS virus is either the cause of SARS or a necessary pre-requisite for disease progression. Whether or not other microbial or other co-factors play a role in progression of the disease remains to be investigated.


We describe for the first time the clinical presentation and complications of SARS. Less than 25% of patients with coronaviral pneumonia had upper respiratory tract symptoms. As expected in atypical pneumonia, both respiratory symptoms and positive auscultatory findings were very disproportional to the chest radiographic findings. Gastrointestinal symptoms were present in 10%. It is relevant that the virus RNA is detected
in faeces of some patients and that coronaviruses have been associated with diarrhoea in animals and humans (Caul EO, Egglestone SI. Further studies on human enteric coronaviruses Arch Virol. 1977; 54: 107-17). The high incidence of deranged liver function test, leucopenia, significant lymphopenia, thrombocytopenia and subsequent evolution into adult respiratory distress syndrome suggests a severe systemic inflammatory damage induced by this hSARS virus. Thus immuno-modulation by steroid may be important to complement the antiviral therapy by ribavirin. In this regard, it is pertinent that severe human disease associated with the avian influenza subtype H5N1, another virus that recently crossed from animals to humans, has also been postulated to have an immunopathological component (Cheung CY, Poon LLM, Lau ASY et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease. Lancet 2002; 360: 1831-1837). In common with H5N1 disease, patients with severe SARS are adults, are significantly more lymphopenic and have parameters of organ dysfunction beyond the respiratory tract (Table 4) (Yuen KY, Chan PKS, Peiris JSM, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998; 351: 467-471).

It is important to note that a window of opportunity of around 8 days exists from the onset of symptoms to respiratory failure. Severe complicated cases are strongly associated with both underlying disease and delayed use of ribavirin and steroid therapy. Following our clinical experience in the initial cases, this combination therapy was started very early in subsequent cases which were largely uncomplicated cases at the time of admission. The overall mortality at the time of writing is only 2% with this treatment regimen. There were still 8 out of 19 complicated cases who had not shown significant response. It is not possible to a detail analysis of the therapeutic response to this combination regimen due to the heterogeneous dosing and time of initiation of therapy.

Other factors associated with severe disease is acquisition of the disease through household contact which may be attributed to a higher dose or duration of viral exposure and the presence of underlying diseases.

The clinical description reported here pertains largely to the more severe cases admitted to hospital. We presently have no data on the full clinical spectrum of the emerging Coronaviridae infection in the community or in an out-patient-setting. The availability of diagnostic tests as described here will help address these questions. In
addition, it will allow questions pertaining to the period of virus shedding (and communicability) during convalescence, the presence of virus in other body fluids and excreta and the presence of virus shedding during the incubation period, to be addressed.

The epidemiological data at present appears to indicate that the virus is spread by droplets or by direct and indirect contact although airborne spread cannot be ruled out in some instances. The finding of infectious virus in the respiratory tract supports this contention. Preliminary evidence also suggests that the virus may be shed in the feces. However, it is important to note that detection of viral RNA does not prove that the virus is viable or transmissible. If viable virus is detectable in the feces, this would be a potentially additional route of transmission that needs to be considered. It is relevant to note that a number of animal coronaviruses are spread via the fecal-oral route (McIntosh K. Coronaviruses: a comparative review. Current Top Microbiol Immunol. 1974; 63: 85-112).

In conclusion, this report provides evidence that a virus in the Coronaviridae family is the etiological agent of SARS.

7. DEPOSIT

A sample of isolated hSARS virus was deposited with China Center for Type Culture Collection (CCTCC) at Wuhan University, Wuhan 430072 in China on April 2, 2003 in accordance with the Budapest Treaty on the Deposit of Microorganisms, and accorded accession No. CCTCC-V200303, which is incorporated herein by reference in its entirety.

8. MARKET POTENTIAL

The hSARS virus can now be grown on a large scale, which allows the development of various diagnostic tests as described hereinabove as well as the development of vaccines and antiviral agents that are effective in preventing, ameliorating or treating SARS. Given the severity of the disease and its rapid global spread, it is highly likely that significant demands for diagnostic tests, therapies and vaccines to battle against the disease, will arise on a global scale. In addition, this virus contains genetic information which is extremely important and valuable for clinical and scientific research applications.
9. EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain many equivalents to the specific embodiments of the invention described herein using no more than routine experimentation. Such equivalents are intended to be encompassed by the following claims.

All publications, patents and patent applications mentioned in this specification are herein incorporated by reference into the specification to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference.

Citation or discussion of a reference herein shall not be construed as an admission that such is prior art to the present invention.
WHAT IS CLAIMED:

1. An isolated hSARS virus having China Center for Type Culture Collection Deposit Accession No. CCTCC-V200303.

2. An isolated hSARS virus comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a nucleotide sequence that hybridizes to SEQ ID NO:1 under stringent condition.

3. An isolated hSARS virus comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:11 or a nucleotide sequence that hybridizes to SEQ ID NO:11 under stringent condition.

4. An isolated hSARS virus comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:13 or a nucleotide sequence that hybridizes to SEQ ID NO:13 under stringent condition.

5. The hSARS virus of any one of claims 1-4 which is killed.

6. The hSARS virus of any one of claims 1-4 which is attenuated.

7. The attenuated hSARS virus of claim 6 whose infectivity is reduced.

8. The attenuated hSARS virus of claim 7 whose infectivity is reduced by at least 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 250-fold, 500-fold, or 10,000-fold.

9. The attenuated hSARS virus of claim 6 whose replication ability is reduced.

10. The attenuated hSARS virus of claim 9 whose replication ability is reduced by at least 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 250-fold, 500-fold, 1,000-fold, or 10,000-fold.

11. The attenuated hSARS virus of claim 6 whose protein synthesis ability is reduced.

12. The attenuated hSARS virus of claim 11 whose protein synthesis ability is reduced by at least 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 250-fold, 500-fold, 1,000-fold, or 10,000-fold.
13. The attenuated hSARS virus of claim 6 whose assembling ability is reduced.

14. The attenuated hSARS virus of claim 13 whose assembling ability is reduced by at least 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 250-fold, 500-fold, 1,000-fold, or 10,000-fold.

15. The attenuated hSARS virus of claim 6 whose cytopathic effect is reduced.

16. The attenuated hSARS virus of claim 15 whose cytopathic effect is reduced by at least 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 250-fold, 500-fold, 1,000-fold, or 10,000-fold.

17. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the hSARS virus of any one of claims 1-4 or a complement thereof.

18. An isolated nucleic acid molecule which hybridizes under stringent conditions to the nucleic acid molecule of claim 17 or a complement thereof.

19. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a complement thereof.

20. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550 or 600 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof.

21. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:2 or a complement of said nucleotide sequence.

22. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:11 or a complement thereof.

23. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150 or 1,200 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:11, or a complement thereof.
24. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:13 or a complement thereof.

25. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 5, 500, 550, 600, 650 or 700 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:13, or a complement thereof.

26. An isolated nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 11, or 13, or a complement thereof, wherein the nucleic acid molecule encodes an amino acid sequence which has a biological activity exhibited by a polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 11 or 13.

27. The nucleic acid molecule of claim 17, wherein the molecule is RNA.

28. The nucleic acid molecule of claim 18, wherein the molecule is RNA.

29. The nucleic acid molecule of any one of claim 19-26, wherein the molecule is RNA.

30. The nucleic acid molecule of claim 17, wherein the molecule is DNA.

31. The nucleic acid molecule of claim 18, wherein the molecule is DNA.

32. The nucleic acid molecule of any one of claims 19-26, wherein the molecule is DNA.

33. An isolated polypeptide encoded by the nucleic acid molecule of claim 17.

34. An isolated polypeptide encoded by the nucleic acid molecule of claim 18.

35. An isolated polypeptide encoded by the nucleic acid molecule of any one of claims 19-26.

36. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2.

37. An isolated polypeptide comprising the amino acid sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 contiguous amino acid residues of the amino acid sequence of SEQ IDNO:2.
38. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:12.

39. An isolated polypeptide comprising an amino acid sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350 or 400 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:12.

40. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:14.

41. An isolated polypeptide comprising an amino acid sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:14.

42. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the hSARS virus of Deposit Accession No: CCTCC-V200303.

43. The isolated antibody of claim 42 or an antigen-binding fragment thereof which neutralizes an hSARS virus.

44. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the hSARS virus of any one of claims 2-4.

45. The isolated antibody of claim 44 or an antigen-binding fragment thereof which neutralizes an hSARS virus.

46. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the polypeptide of claim 33.

47. The isolated antibody of claim 46 or an antigen-binding fragment thereof which neutralizes an hSARS virus.

48. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the polypeptide of claim 34.

49. The isolated antibody of claim 48 or an antigen-binding fragment thereof which neutralizes an hSARS virus.
50. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the polypeptide of claim 35.

51. The isolated antibody of claim 50 or an antigen-binding fragment thereof which neutralizes an hSARS virus.

52. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the polypeptide of any one of claims 36-41.

53. The isolated antibody of claim 52 or an antigen-binding fragment thereof which neutralizes an hSARS virus.

54. A method for detecting the presence of the hSARS virus of any one of claims 1-4 in a biological sample, said method comprising:
   (a) contacting the sample with a compound that selectively binds to said hSARS virus; and
   (b) detecting whether the compound binds to said hSARS virus in the sample.

55. The method of claim 54, wherein the biological sample is selected from the group consisting of cells, blood, serum, plasma, saliva, urine, stool, sputum, and nasopharyngeal aspirates.

56. The method of claim 54, wherein the compound that binds to said virus is an antibody.

57. The method of claim 54, wherein the compound that binds to said virus is a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a complement thereof.

58. The method of claim 54, wherein the compound that binds to said virus is a nucleic acid molecule comprising a nucleotide sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550 or 600 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof.
59. The method of claim 54, wherein the compound that binds to said virus is a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:11 or a complement thereof.

60. The method claim 54, wherein the compound that binds to said virus is a nucleic acid molecule comprising a nucleotide sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150 or 1,200 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:11, or a complement thereof.

61. The method of claim 54, wherein the compound that binds to said virus is a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:13 or a complement thereof.

62. The method of claim 54, wherein the compound that binds to said virus is a nucleic acid molecule comprising a nucleotide sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650 or 700 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:13, or a complement thereof.

63. A method for detecting the presence of the polypeptide of claim 33 in a biological sample, said method comprising:

(a) contacting the biological sample with a compound that selectively binds to said polypeptide; and

(b) detecting whether the compound binds to said polypeptide in the sample.

64. The method of claim 63, wherein the biological sample is selected from the group consisting of cells, blood, serum, plasma, saliva, urine, stool, sputum, and nasopharyngeal aspirates.

65. The method of claim 63, wherein the compound that binds to said polypeptide is an antibody or an antigen-binding fragment thereof.
66. A method for detecting the presence of the polypeptide of claim 34 in a biological sample, said method comprising:

(a) contacting the biological sample with a compound that selectively binds to said polypeptide; and

(b) detecting whether the compound binds to said polypeptide in the sample.

67. The method of claim 66, wherein the biological sample is selected from the group consisting of cells, blood, serum, plasma, saliva, urine, stool, sputum, and nasopharyngeal aspirates.

68. The method of claim 66, wherein the compound that binds to said polypeptide is an antibody or an antigen-binding fragment thereof.

69. A method for detecting the presence of polypeptide of claim 35 in a biological sample, said method comprising:

(a) contacting the biological sample with a compound that selectively binds to said polypeptide; and

(b) detecting whether the compound binds to said polypeptide in the sample.

70. The method of claim 69, wherein the biological sample is selected from the group consisting of cells, blood, serum, plasma, saliva, urine, stool, sputum, and nasopharyngeal aspirates.

71. The method of claim 69, wherein the compound that binds to said polypeptide is an antibody or an antigen-binding fragment thereof.

72. A method for detecting the presence of the polypeptide of claims 36-41 in a biological sample, said method comprising:

(a) contacting the biological sample with a compound that selectively binds to said polypeptide; and

(b) detecting whether the compound binds to said polypeptide in the sample.
73. The method of claim 72, wherein the biological sample is selected from the group consisting of cells, blood, serum, plasma, saliva, urine, stool, sputum, and nasopharyngeal aspirates.

74. The method of claim 72, wherein the compound that binds to said polypeptide is an antibody or an antigen-binding fragment thereof.

75. A method for detecting the presence of a first nucleic acid molecule derived from the hSARS virus of claim 1 in a biological sample, said method comprising:

(a) Contacting the biological sample with a compound that selectively binds to said first nucleic acid molecule; and

(b) detecting whether the compound binds to said first nucleic acid molecule in the sample.

76. The method of claim 75, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a complement thereof.

77. The method of claim 75, wherein the second nucleic acid molecule comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550 or 600 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof.

78. The method of claim 75, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:11 or a complement thereof.

79. The method of claim 75, wherein the second nucleic acid molecule comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150 or 1,200 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:11, or a complement thereof.
80. The method of claim 75, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:13 or a complement thereof.

81. The method of claim 75, wherein the second nucleic acid molecule comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650 or 700 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:13, or a complement thereof.

82. A method for detecting the presence of a first nucleic acid molecule derived from the hSARS virus of claim 2-4 in a biological sample, said method comprising:

(a) Contacting the biological sample with a compound that selectively binds to said first nucleic acid molecule; and

(b) detecting whether the compound binds to said first nucleic acid molecule in the sample.

83. The method of claim 82, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a complement thereof.

84. The method of claim 82, wherein the second nucleic acid molecule comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550 or 600 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof.

85. The method of claim 82, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:11 or a complement thereof.

86. The method of claim 82, wherein the second nucleic acid molecule comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150 or 1,200 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:11, or a complement thereof.
87. The method of claim 82, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:13 or a complement thereof.

88. The method of claim 82, wherein the second nucleic acid molecule comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650 or 700 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:13, or a complement thereof.

89. A host cell infected with the hSARS virus of Deposit Accession No. CCTCC-V200303.

90. The host cell of claim 89 which is a primate cell.

91. The host cell of claim 90 which is a FRhK-4 fetal rhesus monkey kidney cell.

92. A host cell infected with the hSARS virus of any one of claims 2-4.

93. The host cell of claim 92 which is a primate cell.

94. The host cell of claim 93 which is a FRhK-4 fetal rhesus monkey kidney cell.

95. A method of detecting a biological sample the presence of an antibody that immunospecifically binds hSARS virus, said method comprising:

(a) contacting the biological sample with the host cell of claim 89; and

(b) detecting the antibody bound to the cell.

96. A method of detecting a biological sample the presence of an antibody that immunospecifically binds hSARS virus, said method comprising:

(a) contacting the biological sample with the host cell of claim 92; and

(b) detecting the antibody bound to the cell.

97. An immunogenic formulation comprising an immunogenically effective amount of the hSARS virus of claim 5, and a pharmaceutically acceptable carrier.
98. An immunogenic formulation comprising an immunogenically effective amount of the hSARS virus of claim 6, and a pharmaceutically acceptable carrier.

99. An immunogenic formulation comprising an immunogenically effective amount of a protein extract of the hSARS virus of claim 5 or a subunit thereof, and a pharmaceutically acceptable carrier.

100. An immunogenic formulation comprising an immunogenically effective amount of a protein extract of the hSARS virus of claim 6 or a subunit thereof, and a pharmaceutically acceptable carrier.

101. An immunogenic formulation comprising an immunogenically effective amount of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a complement thereof, and a pharmaceutically acceptable carrier.

102. An immunogenic formulation comprising an immunogenically effective amount of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:11 or a complement thereof, and a pharmaceutically acceptable carrier.

103. An immunogenic formulation comprising an immunogenically effective amount of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:13 or a complement thereof, and a pharmaceutically acceptable carrier.

104. An immunogenic formulation comprising an immunogenically effective amount of the polypeptide of claim 33.

105. An immunogenic formulation comprising an immunogenically effective amount of the polypeptide of claim 34.

106. An immunogenic formulation comprising an immunogenically effective amount of polypeptide of claim 35.

107. An immunogenic formulation comprising an immunogenically effective amount of the polypeptide of claim 36-41.
108. A vaccine formulation comprising a therapeutically or prophylactically effective amount of the hSARS virus of claim 5, and a pharmaceutically acceptable carrier.

109. A vaccine formulation comprising a therapeutically or prophylactically effective amount of the hSARS virus of claim 6, and a pharmaceutically acceptable carrier.

110. A vaccine formulation comprising a therapeutically or prophylactically effective amount of a protein extract of the hSARS virus of claim 5 or a subunit thereof, and a pharmaceutically acceptable carrier.

111. A vaccine formulation comprising a therapeutically or prophylactically effective amount of a protein extract of the hSARS virus of claim 6 or a subunit thereof, and a pharmaceutically acceptable carrier.

112. A vaccine formulation comprising an therapeutically or prophylactically effective amount of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a complement thereof; and a pharmaceutically acceptable carrier.

113. A vaccine formulation comprising an therapeutically or prophylactically effective amount of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:11 or a complement thereof, and a pharmaceutically acceptable carrier.

114. A vaccine formulation comprising an therapeutically or prophylactically effective amount of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:13 or a complement thereof, and a pharmaceutically acceptable carrier.

115. A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of an anti-hSARS agent and a pharmaceutically acceptable carrier.

116. The pharmaceutical composition of claim 115, wherein the anti-hSARS agent is an antibody or an antigen-binding fragment thereof which immunospecifically binds to the hSARS virus of Deposit Accession No. CCTCC-V200303, or polypeptides or protein derived therefrom.
117. The pharmaceutical composition of claim 115, wherein the anti-hSARS agent is a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, or a fragment thereof.

118. The pharmaceutical composition of claim 115, wherein the anti-hSARS agent is a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:11 or 13, or a fragment thereof.

119. The pharmaceutical composition of claim 115, wherein the anti-hSARS agent is a polypeptide encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a fragment thereof having a biological activity of said polypeptide.

120. The pharmaceutical composition of claim 115, wherein the anti-hSARS agent is a polypeptide encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:11 or 13, or a fragment thereof having a biological activity of said polypeptide.

121. A kit comprising a container containing the immunogenic formulation of claim 97.

122. A kit comprising a container containing the immunogenic formulation of claim 98.

123. A kit comprising a container containing the immunogenic formulation of claim 99.

124. A kit comprising a container containing the immunogenic formulation of claim 100.

125. A kit comprising a container containing the immunogenic formulation of any one of claims 101-103.

126. A kit comprising a container containing the immunogenic formulation of claim 104.

127. A kit comprising a container containing the immunogenic formulation of claim 105.

128. A kit comprising a container containing the immunogenic formulation of claim 106.

129. A kit comprising a container containing the immunogenic formulation of claim 107.

130. A kit comprising a container containing the vaccine formulation of claim 108.

131. A kit comprising a container containing the vaccine formulation of claim 109.
132. A kit comprising a container containing the vaccine formulation of claim 110.

133. A kit comprising a container containing the vaccine formulation of claim 111.

134. A kit comprising a container containing the vaccine formulation of any one of claims 112-114.

135. A kit comprising a container containing the pharmaceutical composition of claim 115.

136. A method for identifying a subject infected with the hSARS virus of claim 1, comprising:

   (a) obtaining total RNA from a biological sample obtained from the subject

   (b) reverse transcribing the total RNA to obtain cDNA; and

   (c) amplifying the cDNA using a set of primers derived from a nucleotide sequence of the hSARS virus.

137. The method of claim 136, wherein the set of primers are derived from the nucleotide sequence of the genome of the hSARS virus of Deposit Accession No. CCTCC-V200303.

138. The method of claim 136, wherein the set of primers are derived from the nucleotide sequence of SEQ ID NO:1, 11 or 13, or a complement thereof.

139. The method of claim 136, wherein the set of primers have the nucleotide sequence of SEQ ID NO:3 and 4, respectively.

140. A method for identifying a subject infected with the hSARS virus of any one of claims 2-4, comprising:

   (a) obtaining total RNA from a biological sample obtained from the subject

   (b) reverse transcribing the total RNA to obtain cDNA; and

   (c) amplifying the cDNA using a set of primers derived from a nucleotide sequence of the hSARS virus.
141. The method of claim 140, wherein the set of primers are derived from the nucleotide sequence of the genome of the hSARS virus of Deposit Accession No. CCTCC-V200303.

142. The method of claim 140, wherein the set of primers are derived from the nucleotide sequence of SEQ ID NO:1, 11 or 13, or a complement thereof.

143. The method of claim 140, wherein the set of primers have the nucleotide sequence of SEQ ID NOS:3 and 4, respectively.

144. An isolated hSARS virus having the nucleotide sequence of SEQ ID NO:15 or a nucleotide sequence that hybridizes to SEQ ID NO:15 under stringent condition.

145. An isolated nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:15 or a complement thereof.

146. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15, or a complement thereof.

147. An isolated nucleic acid molecule comprising a nucleotide sequence which hybridizes under stringent conditions to the nucleic acid molecule of SEQ ID NO:15 or a complement thereof.

148. An isolated polypeptide encoded by the nucleic acid molecule of claim 145 or a fragment of said nucleic acid molecule.

149. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the polypeptide of claim 148.

150. The isolated antibody of claim 149 or an antigen-binding fragment thereof which neutralizes an hSARS virus.
151. A method for detecting the presence of the hSARS virus of claim 144 in a biological sample, said method comprising:

(a) contacting the sample with a compound that selectively binds to said hSARS virus; and

(b) detecting whether the compound binds to said hSARS virus in the sample.

152. The method of claim 151, wherein the biological sample is selected from the group consisting of cells, blood, serum, plasma, saliva, urine, stool, sputum, and nasopharyngeal aspirates.

153. The method of claim 151, wherein the compound that binds to said virus is an antibody.

154. The method of claim 151, wherein the compound that binds to said virus is a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 11 or 13, or a complement thereof.

155. A method for detecting the presence of the polypeptide of claim 148 in a biological sample, said method comprising:

(a) contacting the biological sample with a compound that selectively binds to said polypeptide; and

(b) detecting whether the compound binds to said polypeptide in the sample.

156. The method of claim 155, wherein the biological sample is selected from the group consisting of cells, blood, serum, plasma, saliva, urine, stool, sputum, and nasopharyngeal aspirates.

157. The method of claim 155, wherein the compound that binds to said polypeptide is an antibody or an antigen-binding fragment thereof.

158. A method for detecting the presence of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:15 or a fragment thereof in a biological sample, said method comprising:
(a) contacting the biological sample with a compound that selectively binds to said nucleic acid molecule; and

(b) detecting whether the compound binds to said nucleic acid molecule in the sample.

159. The method of claim 158, wherein the biological sample is selected from the group consisting of cells, blood, serum, plasma, saliva, urine, stool, sputum, and nasopharyngeal aspirates.

160. A host cell infected with the hSARS virus of claim 144.

161. A vaccine formulation comprising a therapeutically or prophylactically effective amount of the hSARS virus of claim 144 and a pharmaceutically acceptable carrier, wherein the hSARS virus is killed.

162. A vaccine formulation comprising a therapeutically or prophylactically effective amount of the hSARS virus of claim 144 and a pharmaceutically acceptable carrier, wherein the hSARS virus is attenuated.

163. A vaccine formulation comprising a therapeutically or prophylactically effective amount of a protein extract of the hSARS virus of claim 144 and a pharmaceutically acceptable carrier.

164. A vaccine formulation comprising a therapeutically or prophylactically effective amount of the polypeptide of claim 148, and a pharmaceutically acceptable carrier.

165. A vaccine formulation comprising a therapeutically or prophylactically effective amount of a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:15, a complement thereof or a fragment thereof, and a pharmaceutically acceptable carrier.

166. A method for identifying a subject infected with the hSARS virus of claim 144, comprising:

(a) obtaining total RNA from a biological sample obtained from the subject

(b) reverse transcribing the total RNA to obtain cDNA; and
(c) amplifying the cDNA using a set of primers derived from a nucleotide sequence of the hSARS virus.

167. The method of claim 136 or 166, wherein the set of primers are derived from the nucleotide sequence of SEQ ID NO:15, or a complement thereof.
FIG. 1

a cag gac gct gta gct tca aaa atc tta gga tgg cct acg cag act gtt 49
Gln Asp Ala Val Ala Ser Lys Ile Leu Gly Leu Pro Thr Gln Thr Val
1 5 10 15
gat tca tca cag ggt tct gaa tat gac tat gtc ata ttc aca csa act 97
Asp Ser Gln Gly Ser Glu Tyr Asp Tyr Val Ile Phe Thr Gln Thr
20 25 30
act gaa aca gca cac tct tgtaat gtc aac cgc ttc aat gtg gct atc 145
Thr Glu Thr Ala His Ser Cys Asn Val Asn Arg Phe Asn Val Ala Ile
35 40 45
aca agg gca aaa att ggc att tgg tgc ata atg tct gat aga gat ctt 193
Thr Arg Ala Lys Ile Gly Ile Leu Cys Ile Met Ser Asp Arg Asp Leu
50 55 60
tat gac aaa ctt cga ttt aca aatg cta gaa ata cca cgt cgc aat gtg 241
Tyr Asp Lys Leu Gln Phe Thr Ser Leu Glu Ile Pro Arg Arg Asn Val
65 70 75 80
gct aca tta cca gca gaa aat gta act gga ctt ttt aag gac tgt agt 289
Ala Thr Leu Gln Ala Glu Asn Val Thr Gly Leu Phe Lys Asp Cys Ser
90 95
aag atc att act ggt ctt cat cct aca cag gca cct aca cac ctc aag 337
Lys Ile Ile Thr Gly Leu His Pro Thr Glu Ala Pro Thr His Leu Ser
100 105 110
gtt gat ata aaa ttc aag act gaa gga tta tgt gtt gac ata cca ggc 385
Val Asp Ile Lys Phe Lys Thr Glu Gly Leu Cys Val Asp Ile Pro Gly
115 120 125
ata cca aag gag atg acc tac cgt aga ctc atc tct atg atg ggt ttc 433
Ile Pro Lys Asp Met Thr Tyr Arg Leu Ile Ser Met Met Gly Phe
130 135 140
aaa atg aat tac cca gtc aat ggt tac cct aat atg ttt atc acc cgc 481
Lys Met Asn Tyr Gln Val Asn Gly Tyr Pro Asn Met Phe Ile Thr Arg
145 150 155 160
gaa gaa gct att cgt cac gtt cgt gcg tgg att ggc ttt gat gta gag 529
Glu Glu Ala Arg His Arg Gls Val Arg His Gly Arg Val Asp Val Glu
165 170 175
ggc tgt cat gca act aga gat gct ggt ggt act aac cta cct ctc cag 577
Gly Cys His Ala Thr Arg Asp Ala Val Gly Thr Leu Pro Leu Gln
180 185 190
cta gga ttt cct aca ggt gtt aac tta gta gct gta cgg act ggt tat 625
Leu Gly Phe Ser Thr Gly Val Asn Leu Val Ala Val Pro Thr Gly Tyr
195 200 205
gtt gac act gaa aat aac cta 646
Val Asp Thr Glu Asn Asn Leu
210 215
FIG. 2
aaatgtagtagaatactgctgcgtggcgcgtaatagttttgat
Lys Cys Ser Arg Ile Ile Pro Ala Arg Ala Arg Val Glu Cys Phe Asp
 1      5    10    15

aaatcctagaatacatacagtagttttgatcag
Lys Phe Lys Val Asn Ser Thr Leu Glu Gln Tyr Val Phe Cys Thr Val
 20     25    30

aaatgtagcattggctagattgatcatttctaatagcag
Asn Ala Leu Pro Glu Thr Thr Ala Asp Ile Val Phe Asp Glu Ile
 35    40    45

tctatggctactaatattggtttgattctgctaatagctttgt
Ser Met Ala Thr Asn Tyr Asp Leu Ser Val Val Asn Ala Arg Leu Arg
 50    55    60

ccacacattgccctattgcctgcccaatctatcaatccacccc
Asn Ala Lys His Tyr Val Tyr Ile Gly Asp Pro Ala Gln Leu Pro Ala Pro
 65    70    75    80

cgtgcaatctacctggcagccatggtctctttggaact
Thr Leu Leu Thr Lys Gly Thr Leu Glu Pro Glu Tyr Phe Asn Ser
 85    90    95

gttgtgtagctattggccagcacttttcctggaact
Val Cys Arg Leu Met Lys Thr Ile Gly Pro Asp Met Phe Leu Gly Thr
100   105   110

tgtgctgtgctgtgctaggctttgcctgattgacagtctgtgctggatt
Cys Arg Arg Cys Pro Ala Glu Ile Val Asp Thr Val Ser Ala Leu Val
115   120   125

tatgccaatagctaaagcgaccagagaggtcctgctaatcattccttctgcggagt
tyraspasnlysleuelsalhistlysylgsalsalasnlyslysylscysphe
130   135   140

aaatatctactaagggttgattacatgtatgatctcgactcacaatg
Lys Met Phe Tyr Lys Gly Val Ile Thr His Asp Val Ser Ser Ala Ile
145   150   155   160

aacagcctaaagcggtgtgaagaaattcttatacagccaatcct
Asn Arg Pro Glu Ile Gly Val Arg Glu Phe Leu Thr Arg Asn Pro
165   170   175

gctgctggaaagtctgctgatctgctaatctcagaacgggt
Ala Trp Arg Lys Ala Val Phe Ile Ser Pro Tyr Asn Ser Gln Asn Ala
180   185   190

gtaatctataaggctctactaggctctgccagactgtatgattctgattcagaatcattcctgcgcgcggcgt
Val Ala Ser Lys Ile Leu Glu Pro Thr Gln Thr Val Asp Ser Ser
195   200   205

caggttgctgattagtagatct.taagtctccctagaagactaggacaacaacacagct
Gln Gly Ser Glu Tyr Asp Tyr Val Ile Phe Thr Gln Thr Thr Glu Thr
210   215   220

FIG. 8
FIG. 8 Con’t
FIG. 9
FIG. 10 Con't
| 6721 | ttgttcacatt gatgtacttt tactaaagtt acacattctt gaaattagcc tctactacct |
| 6781 | acaactattct caaaatattg ttttaagagt gttgctaaat tatttttggga tggccgcaatt |
| 6841 | aatiaagttga agtcgcccaaa attttttaaa ttggtccaca anacattatg gctatttggtg |
| 6901 | ttaagtattt gctttaacct tctactctgt gtaaatctcg ctttggtcgc aattctatct |
| 6961 | aatatttttgag ttacattctc tggtaaactg gtttaaccagt ctttataaa ttaggttaat |
| 7021 | gttactacta tggattttgct gtaaggggttc ttttttttca gcaattgtttt gagttttggat |
| 7081 | gacactcttg atctatctacc agctcttgaa accaatccaggg ttagctttgg tttctttaaa |
| 7141 | cttagaaggta caattttttg tgtgaggttct gtaagttttg gttaggtgct |
| 7201 | aatattcttt attataaggg ttgcttctgt gtttatgggt ctttctttac tattttgtct |
| 7261 | agtcacccctca taaggccattc tttggcatag ttttttctat caaagcactaca aagcttactag |
| 7321 | cccgctttcctt caagtttag gatgtactatg ttttttttca cttctttctat cttctttctat |
| 7381 | agtcatgttc atatcaagga ttgggctggcc cttttactgt gatgatcttg ctaaatagcg |
| 7441 | atatctggag caaagccttg gttctcccaat tattgttaag gattgaagag gtatctttaat |
| 7501 | gttgtacgtaa ataggggtgc tgctttcttg aatctgctga tctctacatg ctttctttat |
| 7561 | tctttccctat agtctgttct gtagatccgc ttcttcttgc agtctgttct gtagatccgc |
| 7621 | cagttttttaa gacactcctaa ctcttctttgc gctttttttt gctttttttt gctttttttt |
| 7681 | gttgaatattag gcggcttttt actttacttt ctaagacgct gccttttttt gctttttttt |
| 7741 | cttctttttact cttttttttt aatctgctga tctctacatg ctttctttat |
| 7801 | ctgccttaata atacagtatt ttggtgggtc aataacaggt ggcaggtagtt cttgcttttaa |
| 7861 | tcgcttaattc gttgttaataa ttagagcttg gcggagcggt gactcttataa aatctgctga |
| 7921 | cttgcttacc cctactataa agatgtcaag gatgctttta tggctttttg gccttttttt |
| 7981 | gacacttatttt tttttttttt aatctgctga tctctacatg ctttctttat |
| 8041 | gctagtctgg aacactctaa gttttttttt gctttttttt gctttttttt gctttttttt |
| 8101 | gctggcgcag acggtgtttg tggatatggc tttttttttt aatctgctga tctctacatg |
| 8161 | acactatccct atacactactt ctttctttat ctttctttat ctttctttat |
| 8221 | acctataataa agttttaaaa cttttttttt aatctgctga tctctacatg ctttctttat |
| 8281 | goaagcacta atoactcctaat agtctagcaaa agatgctttt cttcttcttt tggctttttt |
| 8341 | aagactcattc tggctttttt cttttttttt aatctgctga tctctacatg ctttctttat |
| 8401 | aacactacatt cttttttttt aatctgctga tctctacatg ctttctttat |
| 8461 | acttaaactc aatctgctga tctctacatg ctttctttat |
| 8521 | gcaactcaatt ataggtttg cttttttttt aatctgctga tctctacatg ctttctttat |
| 8581 | tttttttttt aatctgctga tctctacatg ctttctttat |
| 8641 | gctagctagtt gacactcttt ctcttcttttt tggctttttt aatctgctga tctctacatg |
| 8701 | gcaagttttt ggtggcgttt gttgcttttt ctttctttat ctttctttat |
| 8761 | gotoacacta aacactcttt tttttttttt aatctgctga tctctacatg ctttctttat |
| 8821 | gcaactacatt gttgcttttt ctcttcttttt tggctttttt aatctgctga tctctacatg |
| 8881 | tcgctttttt cttttttttt aatctgctga tctctacatg ctttctttat |
| 8941 | cttttttttt aatctgctga tctctacatg ctttctttat |
| 9001 | cttttttttt aatctgctga tctctacatg ctttctttat |
| 9061 | cttttttttt aatctgctga tctctacatg ctttctttat |
| 9121 | gtaaactcaatt cttttttttt aatctgctga tctctacatg ctttctttat |
| 9181 | tttttttttt aatctgctga tctctacatg ctttctttat |
| 9241 | gttgcttttt cttttttttt aatctgctga tctctacatg ctttctttat |
| 9301 | cttttttttt aatctgctga tctctacatg ctttctttat |
| 9361 | cttttttttt aatctgctga tctctacatg ctttctttat |
FIG. 10 Con’t
14/90

FIG. 10 Con’t
FIG. 10 Con’t
FIG. 10 Con't

16/90
20161 agccocagcte caaataagaa actgcattcttc togaagotgc tattgagatgc ttcatatacgc
20221 gataaaactgc caaggccgatg cacccgagcc cacactttta tggactgttc agtcatggac
20281 aacctggccgg ctcgctatct aagttgtacgc ttagcagctg cttcaagagct tccaacacta
20341 attagaagag aattatctctt atggacacgca cactgtaaaa taataacttaca agactgacg
20401 cccaccggtgc agctgtaataa ttcgctttagt cggactgatc tattactgga acggctgtcc
20461 agatttaaatg ctcgctatctt ttcttttcca cattatacag tctatagcgc aggatcagc
20521 aatgataaaat ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatccgtc
20581 aacgtcaactgc ttcgctttagag agccagcagct ggtttggtgga ttggttgctg cgcactatatgc
20641 aatgtgatcct ttcgctttagag tgggtaattgc aagatcagc agatgtaaag cggataaatgc
20701 aatgtgatcct ttcgctttagag gtaaataagta ttcgactggtc ttcgactggtc tttaataatgtg
20761 ttggtggcct cagccccagct gcctgactgta agacgcagct gcctgactgta aagcatttaagc
20821 ttggtggcct cagccccagct gcctgactgta agacgcagct gcctgactgta aagcatttaagc
20881 ttggtggcct cagccccagct gcctgactgta agacgcagct gcctgactgta aagcatttaagc
20941 ttggtggcct cagccccagct gcctgactgta agacgcagct gcctgactgta aagcatttaagc
20001 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20061 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20121 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20171 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20231 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20281 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20331 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20381 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20431 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20481 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20531 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20581 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20631 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20681 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20731 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20781 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20831 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20881 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20931 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
20981 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
21031 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
21081 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
21131 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
21181 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
21231 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
21281 atgagtggtgc ctcgctatcttct ccagttaaagg gtttggggaag gttgacatgc aagatcagc
FIG. 10 Con't
FIG. 10 Con’t
FIG. 11
FIG. 11 Con't
FIG. 11 Con’t
FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con’t
FIG. 11 Con't
FIG. 11 Con’t
FIG. 11 Con’t
FIG. 11 Con’t
FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con’t
44/90

21001  - ATGTCAGAAAAGAGAAATGACCTCATTAGAAGGTTTTTACCTTTATCTGTGGATTTAATAC
          - M * QKRM T L K G F S L I C V D L *
          - CDKRE * L * RRVFHLHSVWIYK
          - VTKENDSKEGFFFYLYLCGFIFK

21061  - ACGAACAGACGACGACTGCTGCTGCTTCTATACGCTAAGATACAGACAGCATCTTGGAAAG
          - SKN*PWVVL*L*Q*QSLGM
          - AKSTPSGWFSYCSDKDNRAFLEC
          - QKLALGPGSIAVKITEHSWNA

21121  - CTGACCTTTATACAGCTTATGCGCTATTCTCATGTTGAGCAGACGCTTTGGTTGCTAATAG
          - TLFTSLWAQGQLLLQMQ*
          - *PLQAYGPFILMLVDSFCCYKCK
          - DLYKLMLGHPSSWWTAFVNTVN

21181  - ATGCATCTCATGCGAGCAGCATTATTATTAGTGGGCTTTAATAGCTTTTGGGCAAAAGGAC
          - MHHKRFH*LGLTLASRRN
          - CIIIIGISHFNPWNGLSWQAEYGT
          - AASSSEADILQANYLGKPKKEQ

21241  - AAATGATGTCATACCAGACGCTACTAATTCTTCTGGACAGAACCATTGACTATCC
          - KLMHAPCMCLTTFSGGTQILS
          - N*WLYHAC*LHFFLEEHEKSYP
          - IDGYTMHANYIFWRNTPNIQ

21301  - AGTGCTCTCCTCTTATACCTTTGAGAGCAGAATATGCTTCAAATATGAGAACGTG
          - SCLFHIKSLTSANFLNLN**EEL
          - VVFILPFTPHELHEQISSSS*IKRNC
          - LSSYSLEFDMSDKFLKLRGTA

21361  - CTTGAAATCCTGCTTATAGAGGATCATAATCATATATATTCCCTCTTGAGAAG
          - L*CLLLRRIKSMIFILFWKK
          - CVNVS**GESNQ*YDLFSSSGKR
          - VMSLKENQINDMIIYSLLEKG

21421  - GTAGGCTCTATTAGGCTATGAGCTTTGACTGTGTTTCAAGTATTTCTGTTACACA
          - VGLSLEKTEELTFELWPOVIFILLT
          - *AYHRKQQSCGFK*YSCQO
          - RLIJIRENRRVYVSIDSILVNYN

21481  - ACTAACGACAGCATATGTTATATTTCTTATTATACCTCTACTCCACTATGCTAGACCTTG
          - TKTCLFCSYYPFLSSLVTVTL
          - LNEHVFYFILISYSH*W**P*
          - *TNMFIFLLFLDLLTSGSDDL

21541  - ACCGCGCTCGACTTTTCCTCATTGATGCTCATCCTCAATTACACTAAGACTATCTCTCTAC
          - TGAAPLLHMFFKLMLILNLHJL
          - DVFHFP**CSSLHSTFYWI
          - RCTTFDFDDQAPNYTQHTSSM

21601  - TGAGGGGTTACTACTCTGCTAGAAATTTTATAGCTAGACAGACCTTTATTTAACTCAGG
          - **GFGTIILMKFQLDQLFLI*LR
          - EGGGLLS**NFRIRHSLFNSG
          - RGVYYPDEIFRSDTLYLTQD

21661  - ATTTATTTTCTTACATTTTATACGTTAAGTCTTACTCTAGTTTACTCGTTATTTACTCGAG
          - IYFFHFHILMLQGFILLLIRL
          - FISSILF*CYRVSYW*SYVW
          - LFLPFSEYNSVTFGFHTNHTEFG

21721  - GCAAACCCTGCATACCCCAATTGAGGTTTTATTTTTGCTGAGCAGAAACTAAATAG
          - ATDLSYLLRMVFILLPQRNM
          - QPCHTF*GWYLFLCCHREIKC
          - NVPFFKDGIGYFAATEKSNV

2181  - TGTCTGGGTTGTTTTTGGTTCTGACATGAACAACAGAATCCAGATCGTGGTGATTATTA
          - LSVVGFLVLFLPL*TTSHTSR**LL
          - CPWFGLGFPrynHEQOQVTVGDYY
          - VRGWMVGFSMNNKSQSVIII

FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con't
FIG. 11 Con’t
FIG. 11 Cont
FIG. 11 Con't
FIG. 11 Con’t
FIG. 11 Con’t
FIG. 11 Con't
FIG. 12
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
62/90

5881 - GGTCAAGTAAATTTTGTGAAATTTAACCACAAAAATATTTGAGGGTTTTGT - 5940
- GQVIFVRKN*NHQNIKSGKLGFC
- VR*YLSIKKTKTIFQSWGIFT
- SGNICEKLKPPKFKVKVGY

5941 - ACATCTGCTGGATGCAAGGCAACATCTCAGGCTGTGAATCCAGCAGATCTC - 6000
- TFP*LEBTLPCCDVOPVQY
- HLFDSLSEHFCTCVAILFSNST
- ICILT*ANTSRLRSRCSAAIPI

6001 - CGTGAAGTGCACATATGTTATGTCAGGGCAATATCCAAATGACATTAGGG - 6060
- LRVHDVLVVCYSIGEAN*H
- *ECTILLCAKATILEKQIST
- ESRFSVQKLYWRSKLAH

6061 - ATTCATGTAATCTCCGCCGATGTCATCTACATCTCACGGAGGTGTATPGCCATAGAA - 6120
- IQ*NULHRCTYNYNLRRF*FP*K
- FSRISADVHIITYGCGF8HRN
- SVESPQMYILQSTEVLAET

6121 - CAGGCTATTGACTTCTGATATTGATATTGAAATATTAGTAGAGATATAGC - 6180
- QALLL**C*GLKS**V*QWYC
- RHYFCSNAN*KVSRYSNGV1
- GITSVVMLIEKLKVIGIAMVL

6181 - TAGAGTACCAAGCTAGACATTACACATCAAGATACACGTCGACAGCTTTT - 6240
- *SKQLNYQHKLTYKBPQ*IF
- RVSHT*TIST*RHSISHNRF
- E*AIELSAPKDIV*ATIFW

6241 - GGCATCTGACATCAATAAGAATACGGTATGTTACAGCAGACTTCCAGTTAATG - 6300
- G*YYIVIJKLYGN*HAKCQLQ*
- ASTT*RNCMVTSTNAASSNR
- LVLRLRKEVW*LAQMPAPIG

6301 - GANTGCTGCACCTCATAAGAATGTCAGCTGCCTCCTCATTATAAGAAGCTCTGCTGAG - 6360
- ECRTHKKCCHRHAQLL*DSLLE
- NVAILIRSVDMLLSSYKTACLS
- MSHS*EVSTCSAPIQPAPA*V

6361 - TCTGGAAATCCATTGTGGTCAGCTTGATATATAGGCCAACAGTCTGAGTATCTGACAT - 6420
- SGIHCFQ*NICAKLVT*VDLH
- LBYIVSSRYYAPSWCELICIM
- WNTLPFPEYMRQAGV*SA*

6421 - GATATGCTGCTGAGAACATACATTACATTACCTTTGATAAAACGCGCAATGCTGCTGACAT - 6480
- ELL*KHQCS*HLDIEQQQLQM
- NCCRNISAVL*RI*NSNFR*
- IAETSVQOL*YRTSATSEP

6481 - AAGGCCATTGTCCTCAGGAGGATTACATTACCTCACCACAAAAGAGGCTTTAGGCT - 6540
- KHLFQV*LHDLHPKSKVVKCL
- SICSRCNYTYTPKRA*NV*
- ACFVPGVITLTPPEKEQGEMSN

6541 - ATATTTTCAGGTTTTTACGTGAGACCCGACATGAAATCAGAATTCAAATACACGCA - 6600
- IFQMF*YFRISNGESIERNITAK
- ISDVYLSGRTESVUKSETSRBN

6601 - ATTCGGAGAATGCTTACCTCTTGAGAGAAGGAGTTTACACACCGTAGACTGATGC - 6660
- IVMVEISLKKELTHQYQ*V
- LLLKWLKL*RRS*HTSTSES
- CNG*NLFEEGVNTPVPVSP

6661 - CATTAAATATAAAATGTACAGCACTGTGCTTTAAATAAGTGCACTGAGGATATTATTTGTGCTC - 6720
- H*N*N*HTGS*GQWILVH
- IKIKIDTLVNLKNVSFG*FWST
- LKLKTLTHWFILRJVSNDNFQP

FIG. 12 Con't
FIG. 12 Cont'
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
76/90

17641 - AGCTACAGCGCTGCCTAGTACGGCTGGCCGATGCGGTCAATAGGGCAGATATGCGGTAAGAGA - 17700
17643 - SYSLIILGGLGSGGISGIW*R - 17700
17644 - ATACS*ASWAVALAAAYDGKE - 17700
17645 - LQPAPRRPPPQWHKRRHMVMKN - 17700
17646 - ACTAAATTCTGAGAACTATGCGCTGAAAGGCTGAGCGATTTGCTGCGACATAA - 17760
17647 - TGF*SNLSKLSTVIEHFLAQLNSEAIAVRARLSSISSSHN - 17760
17648 - *ILKQ*PPE*HGYRAFPRTT - 17760
17649 - CITTATAGTCATCGACCCTGACCATGATAGCAAAAACAGAAAGAAGACTACTCTTT - 17820
17650 - LINVYSTLH*QNRQKRHNLL - 17820
17651 - LLMSTAPCMDSKTDKRETIF - 17820
17652 - Y*CLQHPAWIAKQTKEKPSS - 17820
17653 - CTGAGAAAGCTCTAGCTTGGTCTGCTTGGCAGAAGAATATCATGTGAGTATGACACATG - 17880
17654 - LESYSFCVFCKKNIVELVLYL - 17880
17655 - KSQLTVPARKFYSRHC - 17880
17656 - RKLQLCLILQEEYHCGVVHVT - 17880
17657 - TGCCCAAAATTTAAGAAGATGTCCTCTACTCTCCTAGTTTGAGAAGACGAGACGACTTACCAC - 17940
17658 - CPQFR*LYSKLLKNREQYH - 17940
17659 - AHNLEDSDSTLS*C*RESTSTT - 17940
17660 - PTI*KMTL*VVEEPRAVPQ - 17940
17661 - AGATGTCATCTTAGGCTAATAGACCTTGATAGCAGCCTGATCTCAGTTGTTT - 18000
17662 - RCALYVHRFRLYSSNLDTWF - 18000
17663 - DVTFTSDILDCIVATLHLG - 18000
17664 - MCTLRQTFQTVQOP*HYVY - 18000
17665 - ACCTCATAACCCACACACCTAATGATCCCTGAGCACTAATAACTATCCTGAGG - 18060
17666 - TSNTQQQLNKVLESINTTLLR - 18060
17667 - PPIVPNLMILAKASILLLGG - 18060
17668 - LQYPTT*C*A*KHQYYS*EA - 18060
17669 - CAAAGACCCCTGTGAGGATCTTACATACATGAAATCCTCAGTGAACACACACAGCTCATAAAC - 18120
17670 - QKPLDGVPHIKFCLCRDQDVVIN - 18120
17671 - KSPWEPFIIYNCSVETK*ST - 18120
17672 - KAPOCSSYTILVRPSSSHKH - 18120
17673 - ACCAGGTAGTACGGCTGAGTACGGTAGGGATACAGAAGAAGCCAGAAGACGCACAGCA - 18180
17674 - TSKSKPVETV*TEKAKVAAA - 18180
17675 - PRVSLK*RLSKQKRPKQ*QQQ - 18180
17676 - QE*A*SGN*YNRKGQSSSNSN - 18180
17677 - ACAATTAGCTAAGGAAACAATAAGAGCAGTAGATACTGTAAGGTTGTCAGCAGTATATAAA - 18240
17678 - TIAT*ETINKHDTRL*GVASNKN - 18240
17679 - QPFFKQ*KTSMIHCKVLVPVIN - 18240
17680 - NLSYNNK*KYTVRCCRQS*I - 18240
17681 - TACCAATCGAAATACCCACACCAATAACACTATGTCCTACCTGCTAAACAATGATATG - 18300
17682 - *QNWVILNTHKYS*KHDD - 18300
17683 - NNN*YSTHTNTIALAKMNIV - 18300
17684 - TMGNTQBTQTL*L*LKT**S - 18300
17685 - CGTGAACGACAAAATAGGATAGGTAGTACAGAAGAAGGCCCAGAAAATAAGACGCACAGCA - 18360
17686 - RNDTRIVRGYRNN*GPHGNS - 18360
17687 - VTTFE*LEVTEIHTKAHMIA - 18360
17688 - *RHQNS*RLQKDLRPTWK*L - 18360
17689 - TTTGATCTAAGCATTACCATGATAGACTTTGTTAAACAGATGTATAGCTACACTGCTGTT - 18420
17690 - L*ISITIDVFRVNKNCKNNDHOC - 18420
17691 - *SKALP*TLTSVMTEISV - 18420
17692 - DLKHYHSLRLCKQV**HSSVS - 18420
17693 - CCACAGACGCCTAGCAACGACTGATACATATACAAACAGTGGCGGATCTAGATGAAATAGAA - 18480
17694 - PNTSSIIINSASCHENQNN - 18480
17695 - QTRLAASS*TVRAVMRISKST - 18480
17696 - KHVD*QHSHHKQAELSE*EAKL

FIG. 12 Con't
19321 - ACCACATGATCCATTAAGGAAAGACCTTTAATGATGATTAGTGCTCTACGACACTG - 19380
- T T * S I K E R T F N G M I R S H G T L
- P H D P L R K E P L M V * L G L M A H *
- H M I H * G K N L * W Y D * V S W H T D
19381 - ATAAACACAGATGATGAAACCATTGATGACTAGACTAAATTGGTGACCGTCTG - 19440
- I N T R W * T I V A C * N * K C L T R L
- * T P D G E P L * H A R T E N V * P G W
- K H Q M V N R C S M L E L K M F D Q V G
19441 - GATACGGCAAAATTTATACTTGTTGCTATTGGTTTAAAGATATCTCAACTTTAACGCTAA - 19500
- D T D K F I L G C L R V S I N F K P K
- I R T N L Y L G V L G L E V S T L S L S
- Y G Q I Y T W V S * G * K Y Q L * A * A
19501 - CAGACAATTTTTGCAATTGAGTGGCCAATGACATGATGATGGGACAATGCAATTGCAA - 19560
- Q T I L H R M W A N N T K L N I S L N K
- R Q F C I E W P I T R S * T L P A * P
- D N F P * N G Q * S H E V E H C O P E Q E
19561 - AAGCTATGTTGATCAGCTATACCCTACTTTAGTTAGGATAAAGCAATGCTCTC - 19620
- K A M V G F A N E Q I F I V R I K H V F
- S Y G W I C E * A D L H S * D * A C L L
19621 - TGGCTGCGAAATGCACTGTTGGAGATACTGTGGTACAATTCATCAACCCATGCAATTGAA - 19680
- C C A N D K M S W T V Y C V I Q F P Q S I K
- A V Q M T C L G Q Y T V S S N H N P L R
- L C K H V L D S I L C H P T T I H E
19681 - AGTGTAGTCCACAGTGTTTCTGTATGACATGCTACGCCCTTCCACCTTGACCTGCAGGATGC - 19740
- S C S S T G Y L Y H A P F N F A * R E C
- V V V P V Q V T C T M H P S T L P D G N A
- L * P H R L L V P C T L Q L C L T G M P
19741 - CATTTCCTAAAAAACACCTCCTCGACACAGACAGATGATTGATGCTGTGGTGGAGTA - 19800
- H F P K T L L Q N S R S D * C L W W L V
19801 - GAGACACATCCAGCCCTGATCGCTGCTTAAAAGTATTTAGGGCCTTTTGGTGGTGGGCAACGACA - 19860
- E N I S T * V A K V I * S L C * V A A S
- R T S A P E L L L K S F R A F A F A K W Q Q A
- E H Q H L S C * S H L E P L L S G S K L
19861 - TGCTTTCAGATGCTGCTGTACATCTGACGCTGCGCTAAATCTTGTTCTGTCTATATAG - 19920
- C F T I A G S I * G S T E I L V L V I * A S R * L V V S K A P L K Y L Y L Y R
- D H D S W * Y L R L H * N T C T C Y I E
19921 - AGCAAGATACCTCTTTTATGCTGTTAGGTCAGAGTGCTCTAGAGCTACCTTAGTTTGTGTA - 19980
- S K I P V L C K W Q Q C L R T Q F E A R Y L L Y C V S G N S V S L R B N F R Y
- Q D T C Y T V * A T V S R Y A I L G T
19981 - CATTTCCTTGTGAGCAGAAAGAGGATAACAAGACGACCTGCTCGAAGGGTACTAATTGTAAC - 20040
- H F L V E Q K G T Q S S L L E G T K C N
- I S L L S K K V H K A A S S S K V L N V T
- F P C * A K R Y T K Q Q P R R Y * M * L
20041 - TCCATATTCAACTGACATCCTTCTCTCTAAGTATGTTGTTAAGACCAATGCGATGCTACG - 20100
- S I K H D S F P P I V K E P M A V I L Q
- P L N M T L F L R * L L K H K N Q W O C F R
- H * T * L F S * D S C * R T N G S A S E
20101 - AGAAATTACAGATATCAAGAGGGCAGGGTCTCTATTCAACAAGGGCAGGAGGAAACGATGCG - 20160
- R N T E Y I D C C Y P K R H N R R R K H G
- E I Q N T * I A V I Q K G T I G E N M A
- K Y R I R H L L L S K K A Q * E K T W Q

FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
FIG. 12 Con't
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N 7/00, C12N 7/04, C07H 21/00, C07K 14/165, G01N 33/569, G01N 33/68, C12Q 1/04, A 61K 39/215, A61P 31/14, A61P 11/00

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N, C07K, G01N, C12Q, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CNPAT, EPDOC, WPI, PAI, CNKI, MEDLINE, GENE BANK

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Arlene R. Collins: &quot;In vitro detection of apoptosis in monocytes/macrophages infected with human coronavirus&quot; CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Vol.9, No.6, Nov. 2002, pages 1392-1395 see the whole document</td>
<td>1-167</td>
</tr>
</tbody>
</table>

* Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search


Date of mailing of the international search report


Name and mailing address of the ISA/CN

6, Xitucheng Road, Jining Bridge, Haidian District, Beijing, 100088, P.R. China

Facsimile No. (86-10) 62019451

Form PCT/ISA/210 (second sheet) (January 2004)

Authorized officer

SONG, Zhigang

Telephone No. (86-010) 62085292
<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Nathalie Arbour, et al. : &quot;Neuroinvasion by human respiratory coronaviruses&quot;</td>
<td>1-167</td>
</tr>
<tr>
<td></td>
<td>see the whole document</td>
<td></td>
</tr>
<tr>
<td>PA</td>
<td>CN-1450164-A</td>
<td>1-167</td>
</tr>
<tr>
<td></td>
<td>22 October 2003 (22.10.2003)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>see claims</td>
<td></td>
</tr>
<tr>
<td>PA</td>
<td>CN-1468955-A</td>
<td>1-167</td>
</tr>
<tr>
<td></td>
<td>21 January 2004 (21.01.2004)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>see claims</td>
<td></td>
</tr>
<tr>
<td></td>
<td>severe acute respiratory syndrome&quot;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SCIENCE, Vol. 300, 30 May 2003, pages 1394-1399</td>
<td></td>
</tr>
<tr>
<td></td>
<td>see the whole document</td>
<td></td>
</tr>
</tbody>
</table>
## INTERNATIONAL SEARCH REPORT

<table>
<thead>
<tr>
<th>Box No.</th>
<th>Nucleotide and/or amino acid sequence(s) (Continuation of item item1.b of the first sheet)</th>
</tr>
</thead>
</table>

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:

   a. type of material  
      - ☒ a sequence listing  
      - ☐ table(s) related to the sequence listing

   b. format of material  
      - ☐ in written format  
      - ☒ in computer readable form

   c. time of filing/furnishing  
      - ☒ contained in the international application as filed  
      - ☐ filed together with the international application in computer readable form  
      - ☐ furnished subsequently to this Authority for the purposes of search

2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:
INTERNATIONAL SEARCH REPORT

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

This International Searching Authority found multiple inventions in this international application, as follows:

   See extra sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on protest
☐ The additional search fees were accompanied by the applicant's protest.
☒ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2004)
## INTERNATIONAL SEARCH REPORT

**International application No.**

PCT/CA2004/000248

---

<table>
<thead>
<tr>
<th>Claim Numbers</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,42-43,89-91,95,136-139,144-167</td>
<td>(completely); 5-18,27-28,30-31,33-34,46-49,54-68,75-81,97-100,104-105,108-111,115-124,126-127,130-133,135 (partially)</td>
</tr>
<tr>
<td>2</td>
<td>2,19-21,36-37,101,112 (completely); 5-18,26-35,44-74,82-88,92-94,96-100,104-111,115-135,140-143 (partially)</td>
</tr>
<tr>
<td>3</td>
<td>3,22-23,38-39,102,113 (completely); 5-18,26-35,44-74,82-88,92-94,96-100,104-111,115-135,140-143 (partially)</td>
</tr>
<tr>
<td>4</td>
<td>4,24-25,40-41,103,114 (completely); 5-18,26-35,44-74,82-88,92-94,96-100,104-111,115-135,140-143 (partially)</td>
</tr>
</tbody>
</table>

---

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. **Claims:**
   - An isolated hSARS virus having the nucleotide sequence of SEQ ID NO :15 (that is, an isolated hSARS virus having China Center for Type Culture Collection Deposit Accession No:CCTCC-V200303) and a host cell infected with the said hSARS virus; an immunogenic or vaccine formulation, a kit or a pharmaceutical composition comprising the said hSARS virus; the said hSARS virus nucleic acid molecule or a complement thereof; a vaccine formulation comprising the virus nucleic acid molecule; an isolated virus polypeptide encoded by the said virus nucleic acid molecule; an immunogenic or vaccine formulation, a kit or a pharmaceutical composition comprising the virus polypeptide; an isolated antibody to the said hSARS virus or the virus polypeptide, a pharmaceutical composition comprising the virus antibody; the method for detecting the presence of the said virus, the virus nucleic acid, the virus polypeptide or the virus antibody; the method for detecting the presence of a first nucleic acid molecule derived from the said virus.

2. **Claims:**
   - An isolated hSARS virus comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO :1; a host cell infected with the said hSARS virus; an immunogenic or vaccine formulation, a kit or a pharmaceutical composition comprising the said hSARS virus; the said hSARS virus nucleic acid molecule or a complement thereof; an isolated virus polypeptide encoded by the said virus nucleic acid molecule; an immunogenic or vaccine formulation or a kit or a pharmaceutical composition comprising the said virus polypeptide; an isolated antibody to the said hSARS virus or the virus polypeptide; the method for detecting the presence of the said virus or the virus polypeptide or the virus antibody; the method for detecting the presence of a first nucleic acid molecule derived from the said virus; an isolated nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO :1 or a complement thereof; an isolated polypeptide encoded by the said nucleic acid molecule; an isolated antibody of the said polypeptide; an immunogenic or vaccine formulation, a kit or a pharmaceutical composition comprising the said nucleic acid or the polypeptide; the method for detecting the presence of the said polypeptide.

3. **Claims:**
   - An isolated hSARS virus comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO :11; a host cell infected with the said hSARS virus; an immunogenic or vaccine formulation, a kit or a pharmaceutical composition comprising the said hSARS virus; the said hSARS virus nucleic acid molecule or a complement thereof; an isolated virus polypeptide encoded by the said virus nucleic acid molecule; an immunogenic or vaccine formulation or a kit or a pharmaceutical composition comprising the said virus polypeptide; an isolated antibody to the said hSARS virus or the virus polypeptide; the method for detecting the presence of the said virus or the virus polypeptide or the virus antibody; the method for detecting the presence of a first nucleic acid molecule derived from the said virus; an isolated nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO :11 or a complement thereof; an isolated polypeptide encoded by the said nucleic acid molecule; an isolated antibody of the said polypeptide; an immunogenic or vaccine formulation, a kit or a pharmaceutical composition comprising the said nucleic acid or the polypeptide; the method for detecting the presence of the said polypeptide.

4. **Claims:**
   - An isolated hSARS virus comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO :13; a host cell infected with the said hSARS virus; an immunogenic or vaccine formulation, a kit or a pharmaceutical composition comprising the said hSARS virus; the said hSARS virus nucleic acid molecule or a complement thereof; an isolated virus polypeptide encoded by the said virus nucleic acid molecule; an immunogenic or vaccine formulation or a kit or a pharmaceutical composition comprising the said virus polypeptide; an isolated antibody to the said hSARS virus or the virus polypeptide; the method for detecting the presence of the said virus or the virus polypeptide or the virus antibody; the method for detecting the presence of a first nucleic acid molecule derived from the said virus; an isolated nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO :13 or a complement thereof; an isolated polypeptide encoded by the said nucleic acid molecule; an isolated antibody of the said polypeptide; an immunogenic or vaccine formulation, a kit or a pharmaceutical composition comprising the said nucleic acid or the polypeptide; the method for detecting the presence of the said polypeptide.

---

Form PCT/ISA /210 (extra sheet) (January 2004)
<table>
<thead>
<tr>
<th>Patent document</th>
<th>Publication date</th>
<th>Patent family Member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CN-1450164-A</td>
<td>22-10-2003</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>CN-1468955-A</td>
<td>21-01-2004</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>